|
|
| G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
increases expression
|
EXP
|
Chlorophyll results in increased expression of GOT1 protein
|
CTD |
PMID:30847814 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871
|
|
| G
|
Gpt
|
glutamic--pyruvic transaminase
|
increases activity
|
EXP
|
Chlorophyll results in increased activity of GPT protein
|
CTD |
PMID:29981020 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
|
|
| G
|
Cat
|
catalase
|
decreases expression
|
EXP
|
Chlorophyll A results in decreased expression of CAT protein
|
CTD |
PMID:30847814 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
| G
|
Gpt
|
glutamic--pyruvic transaminase
|
increases expression
|
EXP
|
Chlorophyll A results in increased expression of GPT protein
|
CTD |
PMID:30847814 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
| G
|
Nos3
|
nitric oxide synthase 3
|
increases expression
|
EXP
|
Chlorophyll A results in increased expression of NOS3 protein
|
CTD |
PMID:30096597 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
| G
|
Sod1
|
superoxide dismutase 1
|
decreases expression
|
EXP
|
Chlorophyll A results in decreased expression of SOD1 protein
|
CTD |
PMID:30847814 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
| G
|
Vegfa
|
vascular endothelial growth factor A
|
increases expression
|
EXP
|
Chlorophyll A results in increased expression of VEGFA protein
|
CTD |
PMID:30096597 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
|
|
| G
|
Abcb6
|
ATP binding cassette subfamily B member 6
|
increases expression
|
ISO
|
Heme results in increased expression of ABCB6 mRNA; Heme results in increased expression of ABCB6 protein
|
CTD |
PMID:17006453 |
|
NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:84,117,220...84,125,526
|
|
| G
|
Adra1a
|
adrenoceptor alpha 1A
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of ADRA1A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr15:45,005,648...45,111,416
Ensembl chr15:45,005,799...45,102,534
|
|
| G
|
Alas1
|
5'-aminolevulinate synthase 1
|
decreases expression multiple interactions
|
ISO
|
Heme results in decreased expression of ALAS1 protein MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein]
|
CTD |
PMID:21659532 |
|
NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642
|
|
| G
|
Alas2
|
5'-aminolevulinate synthase 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of ALAS2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr X:22,890,650...22,914,046
Ensembl chr X:22,890,689...22,914,043
|
|
| G
|
Alb
|
albumin
|
affects binding multiple interactions
|
ISO
|
Heme binds to ALB protein abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein]
|
CTD |
PMID:16336266 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
| G
|
Ambp
|
alpha-1-microglobulin/bikunin precursor
|
increases expression
|
ISO
|
Heme results in increased expression of AMBP mRNA
|
CTD |
PMID:22096585 |
|
NCBI chr 5:81,583,621...81,593,938
Ensembl chr 5:81,583,622...81,593,850
|
|
| G
|
App
|
amyloid beta precursor protein
|
affects binding multiple interactions
|
ISO
|
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme]
|
CTD |
PMID:25211009 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
| G
|
Arhgap31
|
Rho GTPase activating protein 31
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of ARHGAP31 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr11:75,544,176...75,657,087
Ensembl chr11:75,544,040...75,661,076
|
|
| G
|
Asb1
|
ankyrin repeat and SOCS box-containing 1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of ASB1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:99,566,852...99,588,321
Ensembl chr 9:99,567,867...99,583,907
|
|
| G
|
Asxl2
|
ASXL transcriptional regulator 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of ASXL2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 6:32,090,497...32,234,487
Ensembl chr 6:32,145,607...32,227,851
|
|
| G
|
Atp7b
|
ATPase copper transporting beta
|
multiple interactions
|
ISO
|
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of Heme]
|
CTD |
PMID:19888908 |
|
NCBI chr16:76,654,725...76,726,092
Ensembl chr16:76,653,660...76,728,801
|
|
| G
|
Bcar3
|
BCAR3 adaptor protein, NSP family member
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of BCAR3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:213,209,907...213,323,305
Ensembl chr 2:213,209,893...213,323,302
|
|
| G
|
Blvra
|
biliverdin reductase A
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of BLVRA mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:134,793,397...134,819,367
Ensembl chr 3:134,794,203...134,819,785
|
|
| G
|
Bok
|
BCL2 family apoptosis regulator BOK
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of BOK mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833
|
|
| G
|
Ca1
|
carbonic anhydrase 1
|
multiple interactions increases expression
|
EXP
|
[Heme co-treated with Calcium, Dietary] results in increased expression of CAR1 mRNA Heme results in increased expression of CAR1 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr 2:88,550,681...88,593,454
Ensembl chr 2:88,495,475...88,593,454
|
|
| G
|
Camk2b
|
calcium/calmodulin-dependent protein kinase II beta
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of CAMK2B mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr14:85,059,166...85,148,121
Ensembl chr14:85,059,191...85,148,485
|
|
| G
|
Camk2g
|
calcium/calmodulin-dependent protein kinase II gamma
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of CAMK2G mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr15:3,553,238...3,612,310
Ensembl chr15:3,553,294...3,612,310
|
|
| G
|
Ccl2
|
C-C motif chemokine ligand 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of CCL2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
| G
|
Ccl3
|
C-C motif chemokine ligand 3
|
increases secretion
|
ISO
|
Heme analog results in increased secretion of CCL3 protein
|
CTD |
PMID:23355332 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439
|
|
| G
|
Ccl9
|
C-C motif chemokine ligand 9
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of CCL6 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:68,863,994...68,868,928
Ensembl chr10:68,863,995...68,868,877
|
|
| G
|
Ccs
|
copper chaperone for superoxide dismutase
|
multiple interactions
|
ISO
|
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]
|
CTD |
PMID:19039664 |
|
NCBI chr 1:211,543,192...211,564,354
Ensembl chr 1:211,542,701...211,564,260
|
|
| G
|
Cd2
|
Cd2 molecule
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of CD2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:191,399,510...191,412,659
Ensembl chr 2:191,399,510...191,413,665
|
|
| G
|
Cel
|
carboxyl ester lipase
|
decreases expression multiple interactions
|
EXP
|
Heme results in decreased expression of CEL mRNA [Heme co-treated with Calcium, Dietary] results in decreased expression of CEL mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr 3:32,281,518...32,289,019
Ensembl chr 3:32,281,518...32,289,019
|
|
| G
|
Clca1
|
chloride channel accessory 1
|
decreases expression
|
EXP
|
Heme results in decreased expression of CLCA1 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr 2:236,599,022...236,624,714
Ensembl chr 2:236,599,022...236,624,714
|
|
| G
|
Cnot9
|
CCR4-NOT transcription complex subunit 9
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of CNOT9 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:83,533,369...83,558,207
Ensembl chr 9:83,533,369...83,558,197
|
|
| G
|
Cops5
|
COP9 signalosome subunit 5
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of COPS5 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:13,975,198...13,993,391
Ensembl chr 5:13,975,052...13,993,387
|
|
| G
|
Cpox
|
coproporphyrinogen oxidase
|
increases chemical synthesis
|
ISO
|
CPOX protein results in increased chemical synthesis of Heme
|
CTD |
PMID:11248690 |
|
NCBI chr11:55,405,778...55,415,761
Ensembl chr11:55,405,784...55,415,761
|
|
| G
|
Csf2
|
colony stimulating factor 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of CSF2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031
|
|
| G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of CXCL2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
| G
|
Cyb5a
|
cytochrome b5 type A
|
multiple interactions
|
ISO
|
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
|
CTD |
PMID:22390216 |
|
NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094 Ensembl chr18:14,453,966...14,455,094
|
|
| G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions
|
ISO
|
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
|
CTD |
PMID:22390216 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
| G
|
Dgcr8
|
DGCR8 microprocessor complex subunit
|
affects binding
|
ISO
|
DGCR8 protein binds to Heme; DGCR8 protein mutant form binds to Heme
|
CTD |
PMID:21454614 |
|
NCBI chr11:96,208,959...96,241,560
Ensembl chr11:96,209,038...96,241,551
|
|
| G
|
Dnajc7
|
DnaJ heat shock protein family (Hsp40) member C7
|
decreases expression
|
EXP
|
Heme results in decreased expression of DNAJC7 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr10:86,018,977...86,055,419
Ensembl chr10:86,018,961...86,055,489
|
|
| G
|
Dner
|
delta/notch-like EGF repeat containing
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of DNER mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568
|
|
| G
|
Dusp14
|
dual specificity phosphatase 14
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of DUSP14 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:69,433,949...69,463,863
Ensembl chr10:69,426,730...69,462,837
|
|
| G
|
Dusp2
|
dual specificity phosphatase 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of DUSP2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:135,009,636...135,011,821
Ensembl chr 3:135,009,590...135,011,809
|
|
| G
|
Eif2s3
|
eukaryotic translation initiation factor 2 subunit gamma
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of EIF2S3X mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr X:62,910,292...62,933,936
Ensembl chr X:62,910,293...62,934,489
|
|
| G
|
Eno2
|
enolase 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of ENO2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220
|
|
| G
|
Ereg
|
epiregulin
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of EREG mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260
|
|
| G
|
Esrra
|
estrogen related receptor, alpha
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of ESRRA mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811
|
|
| G
|
F10
|
coagulation factor X
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of F10 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr16:83,170,973...83,190,280
Ensembl chr16:83,170,977...83,190,280
|
|
| G
|
F3
|
coagulation factor III, tissue factor
|
increases expression multiple interactions
|
ISO
|
Heme results in increased expression of F3 mRNA Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA]
|
CTD |
PMID:18983524 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369
|
|
| G
|
Fabp2
|
fatty acid binding protein 2
|
multiple interactions increases expression
|
EXP
|
[Heme co-treated with Calcium, Dietary] results in increased expression of FABP2 mRNA Heme results in increased expression of FABP2 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr 2:213,724,629...213,728,686
Ensembl chr 2:213,724,629...213,728,686
|
|
| G
|
Fabp3
|
fatty acid binding protein 3
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of FABP3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881
|
|
| G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of FOS mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
| G
|
Fxyd4
|
FXYD domain-containing ion transport regulator 4
|
decreases expression
|
EXP
|
Heme results in decreased expression of FXYD4 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr 4:152,782,181...152,786,118
Ensembl chr 4:152,782,181...152,786,039
|
|
| G
|
Gfod1
|
Gfo/Idh/MocA-like oxidoreductase domain containing 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of GFOD1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr17:21,606,090...21,710,922
Ensembl chr17:21,605,415...21,710,920
|
|
| G
|
Gipc1
|
GIPC PDZ domain containing family, member 1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of GIPC1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr19:41,380,125...41,392,078
Ensembl chr19:41,380,125...41,391,725
|
|
| G
|
Gpr176
|
G protein-coupled receptor 176
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of GPR176 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:125,690,750...125,791,172
Ensembl chr 3:125,690,751...125,791,172
|
|
| G
|
Gprc5a
|
G protein-coupled receptor, class C, group 5, member A
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of GPRC5A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 4:169,634,896...169,653,627
Ensembl chr 4:169,634,748...169,653,625
|
|
| G
|
Gpt
|
glutamic--pyruvic transaminase
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of GPT mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
| G
|
Gucy1a1
|
guanylate cyclase 1 soluble subunit alpha 1
|
multiple interactions
|
EXP
|
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
|
CTD |
PMID:19466990 |
|
NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737
|
|
| G
|
Gucy1b1
|
guanylate cyclase 1 soluble subunit beta 1
|
multiple interactions
|
ISO EXP
|
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
|
CTD |
PMID:19466990 PMID:22171090 |
|
NCBI chr 2:169,646,897...169,697,060
Ensembl chr 2:169,646,898...169,696,987
|
|
| G
|
Hectd3
|
HECT domain E3 ubiquitin protein ligase 3
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of HECTD3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:135,706,437...135,715,173
Ensembl chr 5:135,706,473...135,714,421
|
|
| G
|
Hk3
|
hexokinase 3
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of HK3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr17:9,602,119...9,620,038
Ensembl chr17:9,605,016...9,620,037
|
|
| G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions increases degradation increases metabolic processing decreases expression decreases abundance increases expression
|
ISO EXP
|
[HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] HMOX1 protein results in increased metabolism of Heme Heme results in decreased expression of HMOX1 mRNA HMOX1 protein results in decreased abundance of Heme [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein]
|
CTD |
PMID:7538129 PMID:8630002 PMID:9224953 PMID:10874044 PMID:12783778 PMID:15242350 PMID:16959961 PMID:17156779 PMID:17292349 PMID:18178725 PMID:19039664 PMID:19136476 PMID:19191707 PMID:19952508 PMID:20638379 PMID:22859313 PMID:32671443 More...
|
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
| G
|
Hpx
|
hemopexin
|
multiple interactions affects binding
|
ISO
|
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]]
|
CTD |
PMID:11213479 PMID:19039664 |
|
NCBI chr 1:169,344,647...169,352,155
Ensembl chr 1:169,344,583...169,352,156
|
|
| G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]]
|
CTD |
PMID:11076874 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
| G
|
Il1a
|
interleukin 1 alpha
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of IL1A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013
|
|
| G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases secretion
|
ISO
|
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein
|
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
| G
|
Il1rl1
|
interleukin 1 receptor-like 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of IL1RL1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:50,157,326...50,222,888
Ensembl chr 9:50,204,551...50,222,891
|
|
| G
|
Il20
|
interleukin 20
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of IL20 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr13:44,933,249...44,936,893
Ensembl chr13:44,933,249...44,936,893
|
|
| G
|
Il6
|
interleukin 6
|
increases expression multiple interactions
|
ISO
|
Heme results in increased expression of IL6 mRNA; Heme results in increased expression of IL6 protein LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
| G
|
Il7r
|
interleukin 7 receptor
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of IL7R mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:60,181,382...60,211,027
|
|
| G
|
Irf3
|
interferon regulatory factor 3
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of IRF3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:104,616,608...104,621,402
Ensembl chr 1:104,616,469...104,621,401
|
|
| G
|
Irf4
|
interferon regulatory factor 4
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of IRF4 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr17:33,930,460...33,948,842
Ensembl chr17:33,930,471...33,948,730
|
|
| G
|
Itln1
|
intelectin 1
|
decreases expression
|
EXP
|
Heme results in decreased expression of ITLN1 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr13:86,464,641...86,490,655
Ensembl chr13:86,464,669...86,490,651
|
|
| G
|
Krt20
|
keratin 20
|
increases expression
|
EXP
|
Heme results in increased expression of KRT20 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr10:84,880,952...84,890,285
Ensembl chr10:84,880,952...84,890,285
|
|
| G
|
Ly96
|
lymphocyte antigen 96
|
affects binding multiple interactions
|
ISO
|
Heme binds to LY96 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]; LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein]; LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr 5:7,365,536...7,397,864
Ensembl chr 5:7,365,557...7,395,816
|
|
| G
|
Lyz2
|
lysozyme 2
|
multiple interactions increases secretion
|
ISO
|
SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein]
|
CTD |
PMID:23355332 |
|
NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011
|
|
| G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation multiple interactions
|
ISO
|
Heme results in increased phosphorylation of MAPK1 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
| G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation multiple interactions
|
ISO
|
Heme results in increased phosphorylation of MAPK3 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
| G
|
Mapk8
|
mitogen-activated protein kinase 8
|
increases phosphorylation multiple interactions
|
ISO
|
Heme results in increased phosphorylation of MAPK8 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
| G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
EXP
|
Heme inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
|
CTD |
PMID:17292349 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
| G
|
Mptx1
|
mucosal pentraxin 1
|
decreases expression multiple interactions
|
EXP
|
Heme results in decreased expression of MPTX1 mRNA Calcium, Dietary inhibits the reaction [Heme results in decreased expression of MPTX1 mRNA]
|
CTD |
PMID:15539406 |
|
NCBI chr13:88,260,335...88,263,869
Ensembl chr13:88,260,335...88,263,869
|
|
| G
|
Mre11
|
MRE11 homolog, double strand break repair nuclease
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of MRE11A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 8:19,900,211...19,961,906
Ensembl chr 8:19,913,772...19,961,904
|
|
| G
|
Mt1a
|
metallothionein 1A
|
decreases response to substance multiple interactions
|
ISO
|
MT1A protein results in decreased susceptibility to Heme [Heme co-treated with HPX protein] affects the activity of MT1 promoter
|
CTD |
PMID:11213479 PMID:11878821 |
|
NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200 Ensembl chr X:79,695,809...79,696,200 Ensembl chr19:79,695,809...79,696,200
|
|
| G
|
Mtf1
|
metal-regulatory transcription factor 1
|
multiple interactions
|
ISO
|
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]
|
CTD |
PMID:11213479 |
|
NCBI chr 5:142,347,024...142,391,810
Ensembl chr 5:142,347,054...142,391,810
|
|
| G
|
Mtmr10
|
myotubularin related protein 10
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of MTMR10 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:127,271,139...127,322,621
Ensembl chr 1:127,270,870...127,322,621
|
|
| G
|
Myd88
|
MYD88, innate immune signal transduction adaptor
|
multiple interactions
|
ISO
|
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230
|
|
| G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
ISO
|
NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]
|
CTD |
PMID:10874044 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
| G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
affects localization
|
ISO
|
Heme analog affects the localization of NFKB1 protein
|
CTD |
PMID:23355332 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
| G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions decreases localization
|
ISO
|
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]
|
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
| G
|
Ngb
|
neuroglobin
|
affects binding
|
ISO
|
Carbon Dioxide binds to [Heme binds to NGB protein]; Heme binds to NGB protein
|
CTD |
PMID:16684569 |
|
NCBI chr 6:112,475,332...112,480,786
Ensembl chr 6:112,475,332...112,480,786
|
|
| G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]]
|
CTD |
PMID:11076874 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
| G
|
Pars2
|
prolyl-tRNA synthetase 2, mitochondrial
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of PARS2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:126,662,882...126,667,981
Ensembl chr 5:126,657,700...126,676,455
|
|
| G
|
Pcsk2
|
proprotein convertase subtilisin/kexin type 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PCSK2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:151,333,938...151,636,628
Ensembl chr 3:151,333,234...151,638,849
|
|
| G
|
Pdgfb
|
platelet derived growth factor subunit B
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of PDGFB mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343
|
|
| G
|
Pgap2
|
post-GPI attachment to proteins 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of PGAP2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:166,003,593...166,030,088
Ensembl chr 1:166,003,523...166,030,088
|
|
| G
|
Phlda1
|
pleckstrin homology-like domain, family A, member 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of PHLDA1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 7:48,853,690...48,855,894
Ensembl chr 7:48,853,260...48,857,542
|
|
| G
|
Pja2
|
praja ring finger ubiquitin ligase 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of PJA2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:111,403,624...111,453,703
Ensembl chr 9:111,403,624...111,453,703
|
|
| G
|
Plekhm1
|
pleckstrin homology and RUN domain containing M1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PLEKHM1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:88,814,699...88,876,570
Ensembl chr10:88,814,699...88,862,544
|
|
| G
|
Plekho1
|
pleckstrin homology domain containing O1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PLEKHO1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:186,233,435...186,242,114
Ensembl chr 2:186,233,452...186,241,354
|
|
| G
|
Plk2
|
polo-like kinase 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PLK2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:43,701,865...43,708,296
|
|
| G
|
Plxna2
|
plexin A2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PLXNA2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453
|
|
| G
|
Pomt1
|
protein-O-mannosyltransferase 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of POMT1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:35,918,370...35,936,330
Ensembl chr 3:35,918,188...35,936,364
|
|
| G
|
Por
|
cytochrome p450 oxidoreductase
|
multiple interactions
|
ISO
|
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
|
CTD |
PMID:22390216 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809
|
|
| G
|
Ppie
|
peptidylprolyl isomerase E
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PPIE mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:140,691,285...140,704,347
Ensembl chr 5:140,683,801...140,740,767
|
|
| G
|
Pstpip2
|
proline-serine-threonine phosphatase-interacting protein 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PSTPIP2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr18:73,585,729...73,671,868
Ensembl chr18:73,585,993...73,671,871
|
|
| G
|
Rab33a
|
RAB33A, member RAS oncogene family
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of RAB33A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr X:132,572,133...132,584,255
Ensembl chr X:132,572,148...132,584,254
|
|
| G
|
Rab3a
|
RAB3A, member RAS oncogene family
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of RAB3A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr16:18,718,164...18,722,273
Ensembl chr16:18,718,167...18,721,842
|
|
| G
|
Rbm39
|
RNA binding motif protein 39
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of RBM39 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:165,123,087...165,156,453
Ensembl chr 3:165,123,095...165,149,397
|
|
| G
|
Rbx1
|
ring-box 1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of RBX1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 7:114,870,893...114,881,194
Ensembl chr 7:114,870,972...114,881,191
|
|
| G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
affects localization increases localization multiple interactions
|
ISO
|
Heme analog affects the localization of RELA protein Heme results in increased localization of RELA protein LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]
|
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
| G
|
Rhebl1
|
RHEB like 1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of RHEBL1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 7:131,905,207...131,910,088
Ensembl chr 7:131,905,207...131,909,199
|
|
| G
|
Rpap1
|
RNA polymerase II associated protein 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of RPAP1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:127,200,450...127,221,985
Ensembl chr 3:127,110,550...127,221,952
|
|
| G
|
Rps6ka2
|
ribosomal protein S6 kinase A2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of RPS6KA2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:55,178,988...55,454,271
Ensembl chr 1:55,179,319...55,454,338
|
|
| G
|
RT1-A2
|
RT1 class Ia, locus A2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of H2-T23 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr20:4,872,720...4,876,425
|
|
| G
|
RT1-Bb
|
RT1 class II, locus Bb
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of H2-AB1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,598,475...4,604,118
|
|
| G
|
RT1-CE16
|
RT1 class I, locus CE16
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of H2-Q1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr20:3,261,656...3,265,548
|
|
| G
|
Setdb1
|
SET domain bifurcated histone lysine methyltransferase 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of SETDB1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:185,587,722...185,619,084
Ensembl chr 2:185,587,722...185,618,982
|
|
| G
|
Slamf7
|
SLAM family member 7
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of SLAMF7 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr13:86,668,060...86,688,222
Ensembl chr13:86,668,060...86,686,341
|
|
| G
|
Slc46a1
|
solute carrier family 46 member 1
|
multiple interactions increases uptake
|
ISO
|
SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] SLC46A1 protein results in increased uptake of Heme
|
CTD |
PMID:17156779 |
|
NCBI chr10:63,859,551...63,865,987
Ensembl chr10:63,859,504...63,866,869
|
|
| G
|
Smarcb1
|
SWI/SNF related BAF chromatin remodeling complex subunit B1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of SMARCB1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr20:12,740,105...12,763,054
Ensembl chr20:12,740,943...12,763,055
|
|
| G
|
Smc4
|
structural maintenance of chromosomes 4
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of SMC4 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:155,550,262...155,578,695
Ensembl chr 2:155,550,262...155,581,937
|
|
| G
|
Srp9
|
signal recognition particle 9
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of SRP9 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr13:96,364,253...96,372,393
Ensembl chr13:96,364,298...96,373,257
|
|
| G
|
Stard4
|
StAR-related lipid transfer domain containing 4
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of STARD4 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr18:25,088,831...25,104,172
Ensembl chr18:25,091,255...25,104,172
|
|
| G
|
Taf7
|
TATA-box binding protein associated factor 7
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of TAF7 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr18:29,704,182...29,713,382
Ensembl chr18:29,705,920...29,712,712
|
|
| G
|
Tdo2
|
tryptophan 2,3-dioxygenase
|
multiple interactions
|
EXP
|
Heme promotes the reaction [pyridine results in increased activity of TDO2 protein]
|
CTD |
PMID:10413312 |
|
NCBI chr 2:169,567,656...169,585,586
Ensembl chr 2:169,567,654...169,585,586
|
|
| G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions affects binding
|
ISO
|
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein] Heme binds to TLR4 protein
|
CTD |
PMID:36115635 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
| G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases expression increases secretion
|
ISO
|
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein] Heme results in increased expression of TNF mRNA; Heme results in increased expression of TNF protein Heme analog results in increased secretion of TNF protein
|
CTD |
PMID:11076874 PMID:23355332 PMID:36115635 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tnfsf13b
|
TNF superfamily member 13b
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of TNFSF13B mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr16:86,164,377...86,195,072
Ensembl chr16:86,164,377...86,194,499
|
|
| G
|
Tollip
|
toll interacting protein
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of TOLLIP mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:206,391,120...206,413,809
Ensembl chr 1:206,380,308...206,411,988
|
|
| G
|
Tuba4a
|
tubulin, alpha 4A
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of TUBA4A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:84,158,871...84,174,041
Ensembl chr 9:84,158,280...84,162,584
|
|
| G
|
Ube2l3
|
ubiquitin-conjugating enzyme E2L 3
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of UBE2L3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr11:97,300,584...97,343,084
Ensembl chr11:97,301,945...97,343,084
|
|
| G
|
Ube2r2
|
ubiquitin-conjugating enzyme E2R 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of UBE2R2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:61,082,552...61,141,099
Ensembl chr 5:61,082,552...61,141,452
|
|
| G
|
Wfikkn2
|
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of WFIKKN2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:79,682,459...79,688,553
Ensembl chr10:79,682,459...79,688,553
|
|
| G
|
Yeats2
|
YEATS domain containing 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of YEATS2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr11:94,247,538...94,333,652
Ensembl chr11:94,247,538...94,333,292
|
|
|
|
| G
|
Abcb6
|
ATP binding cassette subfamily B member 6
|
increases expression
|
ISO
|
Heme results in increased expression of ABCB6 mRNA; Heme results in increased expression of ABCB6 protein
|
CTD |
PMID:17006453 |
|
NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:84,117,220...84,125,526
|
|
| G
|
Adra1a
|
adrenoceptor alpha 1A
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of ADRA1A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr15:45,005,648...45,111,416
Ensembl chr15:45,005,799...45,102,534
|
|
| G
|
Alas1
|
5'-aminolevulinate synthase 1
|
multiple interactions decreases expression
|
ISO
|
MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein]
|
CTD |
PMID:21659532 |
|
NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642
|
|
| G
|
Alas2
|
5'-aminolevulinate synthase 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of ALAS2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr X:22,890,650...22,914,046
Ensembl chr X:22,890,689...22,914,043
|
|
| G
|
Alb
|
albumin
|
multiple interactions affects binding
|
ISO
|
abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein]
|
CTD |
PMID:16336266 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
| G
|
Ambp
|
alpha-1-microglobulin/bikunin precursor
|
increases expression
|
ISO
|
Heme results in increased expression of AMBP mRNA
|
CTD |
PMID:22096585 |
|
NCBI chr 5:81,583,621...81,593,938
Ensembl chr 5:81,583,622...81,593,850
|
|
| G
|
App
|
amyloid beta precursor protein
|
affects binding multiple interactions
|
ISO
|
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme]
|
CTD |
PMID:25211009 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
| G
|
Arhgap31
|
Rho GTPase activating protein 31
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of ARHGAP31 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr11:75,544,176...75,657,087
Ensembl chr11:75,544,040...75,661,076
|
|
| G
|
Asb1
|
ankyrin repeat and SOCS box-containing 1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of ASB1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:99,566,852...99,588,321
Ensembl chr 9:99,567,867...99,583,907
|
|
| G
|
Asxl2
|
ASXL transcriptional regulator 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of ASXL2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 6:32,090,497...32,234,487
Ensembl chr 6:32,145,607...32,227,851
|
|
| G
|
Atp7b
|
ATPase copper transporting beta
|
multiple interactions
|
ISO
|
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of Heme]
|
CTD |
PMID:19888908 |
|
NCBI chr16:76,654,725...76,726,092
Ensembl chr16:76,653,660...76,728,801
|
|
| G
|
Bcar3
|
BCAR3 adaptor protein, NSP family member
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of BCAR3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:213,209,907...213,323,305
Ensembl chr 2:213,209,893...213,323,302
|
|
| G
|
Blvra
|
biliverdin reductase A
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of BLVRA mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:134,793,397...134,819,367
Ensembl chr 3:134,794,203...134,819,785
|
|
| G
|
Bok
|
BCL2 family apoptosis regulator BOK
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of BOK mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833
|
|
| G
|
Ca1
|
carbonic anhydrase 1
|
multiple interactions increases expression
|
EXP
|
[Heme co-treated with Calcium, Dietary] results in increased expression of CAR1 mRNA Heme results in increased expression of CAR1 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr 2:88,550,681...88,593,454
Ensembl chr 2:88,495,475...88,593,454
|
|
| G
|
Camk2b
|
calcium/calmodulin-dependent protein kinase II beta
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of CAMK2B mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr14:85,059,166...85,148,121
Ensembl chr14:85,059,191...85,148,485
|
|
| G
|
Camk2g
|
calcium/calmodulin-dependent protein kinase II gamma
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of CAMK2G mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr15:3,553,238...3,612,310
Ensembl chr15:3,553,294...3,612,310
|
|
| G
|
Ccl2
|
C-C motif chemokine ligand 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of CCL2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
| G
|
Ccl3
|
C-C motif chemokine ligand 3
|
increases secretion
|
ISO
|
Heme analog results in increased secretion of CCL3 protein
|
CTD |
PMID:23355332 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439
|
|
| G
|
Ccl9
|
C-C motif chemokine ligand 9
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of CCL6 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:68,863,994...68,868,928
Ensembl chr10:68,863,995...68,868,877
|
|
| G
|
Ccs
|
copper chaperone for superoxide dismutase
|
multiple interactions
|
ISO
|
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]
|
CTD |
PMID:19039664 |
|
NCBI chr 1:211,543,192...211,564,354
Ensembl chr 1:211,542,701...211,564,260
|
|
| G
|
Cd2
|
Cd2 molecule
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of CD2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:191,399,510...191,412,659
Ensembl chr 2:191,399,510...191,413,665
|
|
| G
|
Cel
|
carboxyl ester lipase
|
decreases expression multiple interactions
|
EXP
|
Heme results in decreased expression of CEL mRNA [Heme co-treated with Calcium, Dietary] results in decreased expression of CEL mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr 3:32,281,518...32,289,019
Ensembl chr 3:32,281,518...32,289,019
|
|
| G
|
Clca1
|
chloride channel accessory 1
|
decreases expression
|
EXP
|
Heme results in decreased expression of CLCA1 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr 2:236,599,022...236,624,714
Ensembl chr 2:236,599,022...236,624,714
|
|
| G
|
Cnot9
|
CCR4-NOT transcription complex subunit 9
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of CNOT9 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:83,533,369...83,558,207
Ensembl chr 9:83,533,369...83,558,197
|
|
| G
|
Cops5
|
COP9 signalosome subunit 5
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of COPS5 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:13,975,198...13,993,391
Ensembl chr 5:13,975,052...13,993,387
|
|
| G
|
Cpox
|
coproporphyrinogen oxidase
|
increases chemical synthesis
|
ISO
|
CPOX protein results in increased chemical synthesis of Heme
|
CTD |
PMID:11248690 |
|
NCBI chr11:55,405,778...55,415,761
Ensembl chr11:55,405,784...55,415,761
|
|
| G
|
Csf2
|
colony stimulating factor 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of CSF2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031
|
|
| G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of CXCL2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
| G
|
Cyb5a
|
cytochrome b5 type A
|
multiple interactions
|
ISO
|
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
|
CTD |
PMID:22390216 |
|
NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094 Ensembl chr18:14,453,966...14,455,094
|
|
| G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions
|
ISO
|
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
|
CTD |
PMID:22390216 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
| G
|
Dgcr8
|
DGCR8 microprocessor complex subunit
|
affects binding
|
ISO
|
DGCR8 protein binds to Heme; DGCR8 protein mutant form binds to Heme
|
CTD |
PMID:21454614 |
|
NCBI chr11:96,208,959...96,241,560
Ensembl chr11:96,209,038...96,241,551
|
|
| G
|
Dnajc7
|
DnaJ heat shock protein family (Hsp40) member C7
|
decreases expression
|
EXP
|
Heme results in decreased expression of DNAJC7 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr10:86,018,977...86,055,419
Ensembl chr10:86,018,961...86,055,489
|
|
| G
|
Dner
|
delta/notch-like EGF repeat containing
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of DNER mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568
|
|
| G
|
Dusp14
|
dual specificity phosphatase 14
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of DUSP14 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:69,433,949...69,463,863
Ensembl chr10:69,426,730...69,462,837
|
|
| G
|
Dusp2
|
dual specificity phosphatase 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of DUSP2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:135,009,636...135,011,821
Ensembl chr 3:135,009,590...135,011,809
|
|
| G
|
Eif2s3
|
eukaryotic translation initiation factor 2 subunit gamma
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of EIF2S3X mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr X:62,910,292...62,933,936
Ensembl chr X:62,910,293...62,934,489
|
|
| G
|
Eno2
|
enolase 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of ENO2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220
|
|
| G
|
Ereg
|
epiregulin
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of EREG mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260
|
|
| G
|
Esrra
|
estrogen related receptor, alpha
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of ESRRA mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811
|
|
| G
|
F10
|
coagulation factor X
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of F10 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr16:83,170,973...83,190,280
Ensembl chr16:83,170,977...83,190,280
|
|
| G
|
F3
|
coagulation factor III, tissue factor
|
multiple interactions increases expression
|
ISO
|
Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA]
|
CTD |
PMID:18983524 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369
|
|
| G
|
Fabp2
|
fatty acid binding protein 2
|
increases expression multiple interactions
|
EXP
|
Heme results in increased expression of FABP2 mRNA [Heme co-treated with Calcium, Dietary] results in increased expression of FABP2 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr 2:213,724,629...213,728,686
Ensembl chr 2:213,724,629...213,728,686
|
|
| G
|
Fabp3
|
fatty acid binding protein 3
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of FABP3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881
|
|
| G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of FOS mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
| G
|
Fxyd4
|
FXYD domain-containing ion transport regulator 4
|
decreases expression
|
EXP
|
Heme results in decreased expression of FXYD4 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr 4:152,782,181...152,786,118
Ensembl chr 4:152,782,181...152,786,039
|
|
| G
|
Gfod1
|
Gfo/Idh/MocA-like oxidoreductase domain containing 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of GFOD1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr17:21,606,090...21,710,922
Ensembl chr17:21,605,415...21,710,920
|
|
| G
|
Gipc1
|
GIPC PDZ domain containing family, member 1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of GIPC1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr19:41,380,125...41,392,078
Ensembl chr19:41,380,125...41,391,725
|
|
| G
|
Gpr176
|
G protein-coupled receptor 176
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of GPR176 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:125,690,750...125,791,172
Ensembl chr 3:125,690,751...125,791,172
|
|
| G
|
Gprc5a
|
G protein-coupled receptor, class C, group 5, member A
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of GPRC5A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 4:169,634,896...169,653,627
Ensembl chr 4:169,634,748...169,653,625
|
|
| G
|
Gpt
|
glutamic--pyruvic transaminase
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of GPT mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
| G
|
Gucy1a1
|
guanylate cyclase 1 soluble subunit alpha 1
|
multiple interactions
|
EXP
|
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
|
CTD |
PMID:19466990 |
|
NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737
|
|
| G
|
Gucy1b1
|
guanylate cyclase 1 soluble subunit beta 1
|
multiple interactions
|
ISO EXP
|
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
|
CTD |
PMID:19466990 PMID:22171090 |
|
NCBI chr 2:169,646,897...169,697,060
Ensembl chr 2:169,646,898...169,696,987
|
|
| G
|
Hectd3
|
HECT domain E3 ubiquitin protein ligase 3
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of HECTD3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:135,706,437...135,715,173
Ensembl chr 5:135,706,473...135,714,421
|
|
| G
|
Hk3
|
hexokinase 3
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of HK3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr17:9,602,119...9,620,038
Ensembl chr17:9,605,016...9,620,037
|
|
| G
|
Hmox1
|
heme oxygenase 1
|
decreases expression multiple interactions increases degradation decreases abundance increases metabolic processing increases expression
|
ISO EXP
|
Heme results in decreased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein] HMOX1 protein results in increased degradation of Heme HMOX1 protein results in decreased abundance of Heme HMOX1 protein results in increased metabolism of Heme [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein
|
CTD |
PMID:7538129 PMID:8630002 PMID:9224953 PMID:10874044 PMID:12783778 PMID:15242350 PMID:16959961 PMID:17156779 PMID:17292349 PMID:18178725 PMID:19039664 PMID:19136476 PMID:19191707 PMID:19952508 PMID:20638379 PMID:22859313 PMID:32671443 More...
|
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
| G
|
Hpx
|
hemopexin
|
multiple interactions affects binding
|
ISO
|
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]]
|
CTD |
PMID:11213479 PMID:19039664 |
|
NCBI chr 1:169,344,647...169,352,155
Ensembl chr 1:169,344,583...169,352,156
|
|
| G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]]
|
CTD |
PMID:11076874 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
| G
|
Il1a
|
interleukin 1 alpha
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of IL1A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013
|
|
| G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases secretion
|
ISO
|
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein
|
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
| G
|
Il1rl1
|
interleukin 1 receptor-like 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of IL1RL1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:50,157,326...50,222,888
Ensembl chr 9:50,204,551...50,222,891
|
|
| G
|
Il20
|
interleukin 20
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of IL20 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr13:44,933,249...44,936,893
Ensembl chr13:44,933,249...44,936,893
|
|
| G
|
Il6
|
interleukin 6
|
increases expression multiple interactions
|
ISO
|
Heme results in increased expression of IL6 mRNA; Heme results in increased expression of IL6 protein LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
| G
|
Il7r
|
interleukin 7 receptor
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of IL7R mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:60,181,382...60,211,027
|
|
| G
|
Irf3
|
interferon regulatory factor 3
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of IRF3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:104,616,608...104,621,402
Ensembl chr 1:104,616,469...104,621,401
|
|
| G
|
Irf4
|
interferon regulatory factor 4
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of IRF4 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr17:33,930,460...33,948,842
Ensembl chr17:33,930,471...33,948,730
|
|
| G
|
Itln1
|
intelectin 1
|
decreases expression
|
EXP
|
Heme results in decreased expression of ITLN1 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr13:86,464,641...86,490,655
Ensembl chr13:86,464,669...86,490,651
|
|
| G
|
Krt20
|
keratin 20
|
increases expression
|
EXP
|
Heme results in increased expression of KRT20 mRNA
|
CTD |
PMID:15539406 |
|
NCBI chr10:84,880,952...84,890,285
Ensembl chr10:84,880,952...84,890,285
|
|
| G
|
Ly96
|
lymphocyte antigen 96
|
affects binding multiple interactions
|
ISO
|
Heme binds to LY96 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]; LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein]; LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr 5:7,365,536...7,397,864
Ensembl chr 5:7,365,557...7,395,816
|
|
| G
|
Lyz2
|
lysozyme 2
|
increases secretion multiple interactions
|
ISO
|
Heme analog results in increased secretion of LYZ protein SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein]
|
CTD |
PMID:23355332 |
|
NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011
|
|
| G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation
|
ISO
|
LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
| G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation multiple interactions
|
ISO
|
Heme results in increased phosphorylation of MAPK3 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
| G
|
Mapk8
|
mitogen-activated protein kinase 8
|
multiple interactions increases phosphorylation
|
ISO
|
LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
| G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
EXP
|
Heme inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
|
CTD |
PMID:17292349 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
| G
|
Mptx1
|
mucosal pentraxin 1
|
decreases expression multiple interactions
|
EXP
|
Heme results in decreased expression of MPTX1 mRNA Calcium, Dietary inhibits the reaction [Heme results in decreased expression of MPTX1 mRNA]
|
CTD |
PMID:15539406 |
|
NCBI chr13:88,260,335...88,263,869
Ensembl chr13:88,260,335...88,263,869
|
|
| G
|
Mre11
|
MRE11 homolog, double strand break repair nuclease
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of MRE11A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 8:19,900,211...19,961,906
Ensembl chr 8:19,913,772...19,961,904
|
|
| G
|
Mt1a
|
metallothionein 1A
|
decreases response to substance multiple interactions
|
ISO
|
MT1A protein results in decreased susceptibility to Heme [Heme co-treated with HPX protein] affects the activity of MT1 promoter
|
CTD |
PMID:11213479 PMID:11878821 |
|
NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200 Ensembl chr X:79,695,809...79,696,200 Ensembl chr19:79,695,809...79,696,200
|
|
| G
|
Mtf1
|
metal-regulatory transcription factor 1
|
multiple interactions
|
ISO
|
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]
|
CTD |
PMID:11213479 |
|
NCBI chr 5:142,347,024...142,391,810
Ensembl chr 5:142,347,054...142,391,810
|
|
| G
|
Mtmr10
|
myotubularin related protein 10
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of MTMR10 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:127,271,139...127,322,621
Ensembl chr 1:127,270,870...127,322,621
|
|
| G
|
Myd88
|
MYD88, innate immune signal transduction adaptor
|
multiple interactions
|
ISO
|
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230
|
|
| G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
ISO
|
NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]
|
CTD |
PMID:10874044 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
| G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
affects localization
|
ISO
|
Heme analog affects the localization of NFKB1 protein
|
CTD |
PMID:23355332 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
| G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions decreases localization
|
ISO
|
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]
|
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
| G
|
Ngb
|
neuroglobin
|
affects binding
|
ISO
|
Carbon Dioxide binds to [Heme binds to NGB protein]; Heme binds to NGB protein
|
CTD |
PMID:16684569 |
|
NCBI chr 6:112,475,332...112,480,786
Ensembl chr 6:112,475,332...112,480,786
|
|
| G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]]
|
CTD |
PMID:11076874 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
| G
|
Pars2
|
prolyl-tRNA synthetase 2, mitochondrial
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of PARS2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:126,662,882...126,667,981
Ensembl chr 5:126,657,700...126,676,455
|
|
| G
|
Pcsk2
|
proprotein convertase subtilisin/kexin type 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PCSK2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:151,333,938...151,636,628
Ensembl chr 3:151,333,234...151,638,849
|
|
| G
|
Pdgfb
|
platelet derived growth factor subunit B
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of PDGFB mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343
|
|
| G
|
Pgap2
|
post-GPI attachment to proteins 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of PGAP2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:166,003,593...166,030,088
Ensembl chr 1:166,003,523...166,030,088
|
|
| G
|
Phlda1
|
pleckstrin homology-like domain, family A, member 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of PHLDA1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 7:48,853,690...48,855,894
Ensembl chr 7:48,853,260...48,857,542
|
|
| G
|
Pja2
|
praja ring finger ubiquitin ligase 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of PJA2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:111,403,624...111,453,703
Ensembl chr 9:111,403,624...111,453,703
|
|
| G
|
Plekhm1
|
pleckstrin homology and RUN domain containing M1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PLEKHM1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:88,814,699...88,876,570
Ensembl chr10:88,814,699...88,862,544
|
|
| G
|
Plekho1
|
pleckstrin homology domain containing O1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PLEKHO1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:186,233,435...186,242,114
Ensembl chr 2:186,233,452...186,241,354
|
|
| G
|
Plk2
|
polo-like kinase 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PLK2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:43,701,865...43,708,296
|
|
| G
|
Plxna2
|
plexin A2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PLXNA2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453
|
|
| G
|
Pomt1
|
protein-O-mannosyltransferase 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of POMT1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:35,918,370...35,936,330
Ensembl chr 3:35,918,188...35,936,364
|
|
| G
|
Por
|
cytochrome p450 oxidoreductase
|
multiple interactions
|
ISO
|
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
|
CTD |
PMID:22390216 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809
|
|
| G
|
Ppie
|
peptidylprolyl isomerase E
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PPIE mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:140,691,285...140,704,347
Ensembl chr 5:140,683,801...140,740,767
|
|
| G
|
Pstpip2
|
proline-serine-threonine phosphatase-interacting protein 2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of PSTPIP2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr18:73,585,729...73,671,868
Ensembl chr18:73,585,993...73,671,871
|
|
| G
|
Rab33a
|
RAB33A, member RAS oncogene family
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of RAB33A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr X:132,572,133...132,584,255
Ensembl chr X:132,572,148...132,584,254
|
|
| G
|
Rab3a
|
RAB3A, member RAS oncogene family
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of RAB3A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr16:18,718,164...18,722,273
Ensembl chr16:18,718,167...18,721,842
|
|
| G
|
Rbm39
|
RNA binding motif protein 39
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of RBM39 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:165,123,087...165,156,453
Ensembl chr 3:165,123,095...165,149,397
|
|
| G
|
Rbx1
|
ring-box 1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of RBX1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 7:114,870,893...114,881,194
Ensembl chr 7:114,870,972...114,881,191
|
|
| G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
affects localization multiple interactions increases localization
|
ISO
|
Heme analog affects the localization of RELA protein LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]
|
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
| G
|
Rhebl1
|
RHEB like 1
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of RHEBL1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 7:131,905,207...131,910,088
Ensembl chr 7:131,905,207...131,909,199
|
|
| G
|
Rpap1
|
RNA polymerase II associated protein 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of RPAP1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 3:127,200,450...127,221,985
Ensembl chr 3:127,110,550...127,221,952
|
|
| G
|
Rps6ka2
|
ribosomal protein S6 kinase A2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of RPS6KA2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:55,178,988...55,454,271
Ensembl chr 1:55,179,319...55,454,338
|
|
| G
|
RT1-A2
|
RT1 class Ia, locus A2
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of H2-T23 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr20:4,872,720...4,876,425
|
|
| G
|
RT1-Bb
|
RT1 class II, locus Bb
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of H2-AB1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,598,475...4,604,118
|
|
| G
|
RT1-CE16
|
RT1 class I, locus CE16
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of H2-Q1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr20:3,261,656...3,265,548
|
|
| G
|
Setdb1
|
SET domain bifurcated histone lysine methyltransferase 1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of SETDB1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:185,587,722...185,619,084
Ensembl chr 2:185,587,722...185,618,982
|
|
| G
|
Slamf7
|
SLAM family member 7
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of SLAMF7 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr13:86,668,060...86,688,222
Ensembl chr13:86,668,060...86,686,341
|
|
| G
|
Slc46a1
|
solute carrier family 46 member 1
|
multiple interactions increases uptake
|
ISO
|
SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] SLC46A1 protein results in increased uptake of Heme
|
CTD |
PMID:17156779 |
|
NCBI chr10:63,859,551...63,865,987
Ensembl chr10:63,859,504...63,866,869
|
|
| G
|
Smarcb1
|
SWI/SNF related BAF chromatin remodeling complex subunit B1
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of SMARCB1 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr20:12,740,105...12,763,054
Ensembl chr20:12,740,943...12,763,055
|
|
| G
|
Smc4
|
structural maintenance of chromosomes 4
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of SMC4 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 2:155,550,262...155,578,695
Ensembl chr 2:155,550,262...155,581,937
|
|
| G
|
Srp9
|
signal recognition particle 9
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of SRP9 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr13:96,364,253...96,372,393
Ensembl chr13:96,364,298...96,373,257
|
|
| G
|
Stard4
|
StAR-related lipid transfer domain containing 4
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of STARD4 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr18:25,088,831...25,104,172
Ensembl chr18:25,091,255...25,104,172
|
|
| G
|
Taf7
|
TATA-box binding protein associated factor 7
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of TAF7 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr18:29,704,182...29,713,382
Ensembl chr18:29,705,920...29,712,712
|
|
| G
|
Tdo2
|
tryptophan 2,3-dioxygenase
|
multiple interactions
|
EXP
|
Heme promotes the reaction [pyridine results in increased activity of TDO2 protein]
|
CTD |
PMID:10413312 |
|
NCBI chr 2:169,567,656...169,585,586
Ensembl chr 2:169,567,654...169,585,586
|
|
| G
|
Tlr4
|
toll-like receptor 4
|
affects binding multiple interactions
|
ISO
|
Heme binds to TLR4 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein]
|
CTD |
PMID:36115635 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
| G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases expression increases secretion
|
ISO
|
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein] Heme results in increased expression of TNF mRNA; Heme results in increased expression of TNF protein Heme analog results in increased secretion of TNF protein
|
CTD |
PMID:11076874 PMID:23355332 PMID:36115635 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tnfsf13b
|
TNF superfamily member 13b
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of TNFSF13B mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr16:86,164,377...86,195,072
Ensembl chr16:86,164,377...86,194,499
|
|
| G
|
Tollip
|
toll interacting protein
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of TOLLIP mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 1:206,391,120...206,413,809
Ensembl chr 1:206,380,308...206,411,988
|
|
| G
|
Tuba4a
|
tubulin, alpha 4A
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of TUBA4A mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 9:84,158,871...84,174,041
Ensembl chr 9:84,158,280...84,162,584
|
|
| G
|
Ube2l3
|
ubiquitin-conjugating enzyme E2L 3
|
increases expression
|
ISO
|
Heme metabolite results in increased expression of UBE2L3 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr11:97,300,584...97,343,084
Ensembl chr11:97,301,945...97,343,084
|
|
| G
|
Ube2r2
|
ubiquitin-conjugating enzyme E2R 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of UBE2R2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr 5:61,082,552...61,141,099
Ensembl chr 5:61,082,552...61,141,452
|
|
| G
|
Wfikkn2
|
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of WFIKKN2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr10:79,682,459...79,688,553
Ensembl chr10:79,682,459...79,688,553
|
|
| G
|
Yeats2
|
YEATS domain containing 2
|
decreases expression
|
ISO
|
Heme metabolite results in decreased expression of YEATS2 mRNA
|
CTD |
PMID:19191707 |
|
NCBI chr11:94,247,538...94,333,652
Ensembl chr11:94,247,538...94,333,292
|
|
|
|
| G
|
Aco1
|
aconitase 1
|
decreases activity
|
EXP
|
Hemin results in decreased activity of ACO1 protein
|
CTD |
PMID:16568477 |
|
NCBI chr 5:60,055,895...60,111,920
Ensembl chr 5:60,055,866...60,112,600
|
|
| G
|
Aco2
|
aconitase 2
|
increases expression
|
EXP
|
Hemin results in increased expression of ACO2 protein
|
CTD |
PMID:16568477 |
|
NCBI chr 7:115,265,816...115,308,931
Ensembl chr 7:115,265,791...115,308,892
|
|
| G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
increases secretion
|
EXP
|
Hemin results in increased secretion of ADIPOQ protein
|
CTD |
PMID:20016031 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169
|
|
| G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein]
|
CTD |
PMID:18215737 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
| G
|
Alas1
|
5'-aminolevulinate synthase 1
|
increases degradation
|
EXP
|
Hemin results in increased degradation of ALAS1 protein
|
CTD |
PMID:17761694 |
|
NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642
|
|
| G
|
Alas2
|
5'-aminolevulinate synthase 2
|
increases expression multiple interactions
|
ISO
|
Hemin results in increased expression of ALAS2 mRNA [catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol promotes the reaction [Hemin results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of ALAS2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of ALAS2 mRNA]
|
CTD |
PMID:23973255 PMID:24141029 PMID:28552822 |
|
NCBI chr X:22,890,650...22,914,046
Ensembl chr X:22,890,689...22,914,043
|
|
| G
|
Alb
|
albumin
|
affects binding
|
ISO
|
Hemin binds to ALB protein
|
CTD |
PMID:10506189 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
| G
|
Aldh2
|
aldehyde dehydrogenase 2 family member
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [Nitroglycerin results in decreased activity of ALDH2 protein]
|
CTD |
PMID:17541025 |
|
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219
|
|
| G
|
Alpl
|
alkaline phosphatase, biomineralization associated
|
decreases expression
|
EXP
|
Hemin results in decreased expression of ALPL mRNA
|
CTD |
PMID:20020468 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167
|
|
| G
|
Arl6ip5
|
ARF like GTPase 6 interacting protein 5
|
increases expression
|
ISO
|
Hemin results in increased expression of ARL6IP5 protein
|
CTD |
PMID:16430862 |
|
NCBI chr 4:131,365,320...131,395,311
Ensembl chr 4:131,367,289...131,400,130
|
|
| G
|
Bach1
|
BTB domain and CNC homolog 1
|
multiple interactions affects localization increases expression
|
ISO
|
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] affects the localization of BACH1 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of BACH1 protein; [Hemin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of BACH1 mRNA; BACH1 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; Hemin inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BACH1 protein]; Hemin results in decreased localization of and results in decreased activity of BACH1 protein Hemin affects the localization of BACH1 protein Hemin results in increased expression of BACH1 mRNA; Hemin results in increased expression of BACH1 protein
|
CTD |
PMID:18550526 PMID:31518892 PMID:33434570 PMID:36096218 |
|
NCBI chr11:40,425,721...40,461,118
Ensembl chr11:40,425,664...40,461,277
|
|
| G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions increases expression
|
ISO EXP
|
Hemin promotes the reaction [Cisplatin results in increased expression of BAX protein] Hemin results in increased expression of BAX protein Hemin inhibits the reaction [lead acetate results in increased expression of BAX protein]
|
CTD |
PMID:27815112 PMID:29797346 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
| G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions
|
ISO EXP
|
Hemin results in decreased expression of BCL2 protein Hemin inhibits the reaction [lead acetate results in decreased expression of BCL2 protein]
|
CTD |
PMID:27815112 PMID:29797346 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
| G
|
Bglap
|
bone gamma-carboxyglutamate protein
|
decreases expression multiple interactions
|
EXP
|
Hemin results in decreased expression of BGLAP mRNA 15-deoxyprostaglandin J2 inhibits the reaction [Hemin results in decreased expression of BGLAP mRNA]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased expression of BGLAP mRNA]
|
CTD |
PMID:20020468 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318
|
|
| G
|
Birc2
|
baculoviral IAP repeat-containing 2
|
increases expression
|
ISO
|
Hemin results in increased expression of BIRC2 protein
|
CTD |
PMID:14647439 |
|
NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911
|
|
| G
|
Casp3
|
caspase 3
|
multiple interactions increases cleavage
|
EXP ISO
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in increased cleavage of CASP3 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]] Hemin promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Hemin results in increased expression of and results in increased cleavage of CASP3 protein Hemin results in increased cleavage of CASP3 protein [SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form
|
CTD |
PMID:17173083 PMID:18845130 PMID:19150641 PMID:19520142 PMID:26747958 PMID:27815112 PMID:31054940 PMID:39486598 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
| G
|
Casp9
|
caspase 9
|
increases expression
|
ISO
|
Hemin results in increased expression of CASP9 protein
|
CTD |
PMID:39486598 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
| G
|
Cat
|
catalase
|
multiple interactions
|
EXP ISO
|
Hemin inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein] Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Hemin inhibits the reaction [Cisplatin results in decreased activity of CAT protein]
|
CTD |
PMID:19150641 PMID:27815112 PMID:35691465 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
| G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions
|
ISO
|
Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]
|
CTD |
PMID:35691465 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
| G
|
Cdh1
|
cadherin 1
|
multiple interactions
|
EXP
|
[Hemin co-treated with indole-3-carbinol co-treated with 1,2-Dimethylhydrazine] affects the expression of CDH1 mRNA
|
CTD |
PMID:29269057 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
| G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression multiple interactions
|
ISO
|
Hemin results in increased expression of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Hemin results in increased expression of CDKN1A protein]
|
CTD |
PMID:14647439 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
| G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
decreases degradation
|
ISO
|
Hemin results in decreased degradation of CDKN1B protein
|
CTD |
PMID:17283133 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498
|
|
| G
|
Cebpa
|
CCAAT/enhancer binding protein alpha
|
multiple interactions increases expression
|
ISO
|
HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA]
|
CTD |
PMID:29749404 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309
|
|
| G
|
Chd4
|
chromodomain helicase DNA binding protein 4
|
multiple interactions
|
ISO
|
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein]; [Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [thiamet G results in increased O-linked glycosylation of CHD4 protein]; [Hemin co-treated with hexamethylene bisacetamide] results in decreased O-linked glycosylation of CHD4 protein
|
CTD |
PMID:27231347 |
|
NCBI chr 4:159,584,623...159,617,867
Ensembl chr 4:159,584,654...159,617,866
|
|
| G
|
Comt
|
catechol-O-methyltransferase
|
multiple interactions
|
ISO
|
COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA]
|
CTD |
PMID:24141029 |
|
NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533
|
|
| G
|
Crh
|
corticotropin releasing hormone
|
increases secretion multiple interactions
|
ISO
|
Hemin results in increased secretion of CRH protein mesoporphyrin IX analog inhibits the reaction [Hemin results in increased secretion of CRH protein]
|
CTD |
PMID:11232018 |
|
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386
|
|
| G
|
Cybb
|
cytochrome b-245 beta chain
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB mRNA]; Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]]
|
CTD |
PMID:23272707 |
|
NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065
|
|
| G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
ISO EXP
|
Hemin inhibits the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [Mercuric Chloride inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [sodium arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]
|
CTD |
PMID:20188822 PMID:20837117 PMID:22120038 PMID:22159698 PMID:26747958 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
| G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions
|
EXP
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP1A2 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]]
|
CTD |
PMID:22159698 PMID:26747958 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
| G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
multiple interactions
|
EXP
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP2B1 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP2B1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP2B1 protein]
|
CTD |
PMID:26747958 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
| G
|
Cyp2d4
|
cytochrome P450, family 2, subfamily d, polypeptide 4
|
multiple interactions
|
ISO
|
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]
|
CTD |
PMID:11368792 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837
|
|
| G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions
|
EXP ISO
|
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 protein] Hemin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein]
|
CTD |
PMID:19325051 PMID:26747958 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
| G
|
Ddit3
|
DNA-damage inducible transcript 3
|
multiple interactions increases expression
|
EXP ISO
|
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of DDIT3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of DDIT3 protein] Hemin results in increased expression of DDIT3 mRNA
|
CTD |
PMID:26747958 PMID:29749404 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
| G
|
Dlg1
|
discs large MAGUK scaffold protein 1
|
multiple interactions
|
ISO
|
Hemin inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of DLG1 protein]
|
CTD |
PMID:36096218 |
|
NCBI chr11:82,416,853...82,607,797
Ensembl chr11:82,416,853...82,607,797
|
|
| G
|
Efna1
|
ephrin A1
|
multiple interactions
|
ISO
|
[hydroquinone co-treated with Hemin] affects the expression of EFNA1 mRNA
|
CTD |
PMID:32198055 |
|
NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726
|
|
| G
|
Eif2ak3
|
eukaryotic translation initiation factor 2 alpha kinase 3
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased phosphorylation of EIF2AK3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased phosphorylation of EIF2AK3 protein]
|
CTD |
PMID:26747958 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268
|
|
| G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression
|
ISO
|
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Hemin results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [Hemin results in increased expression of FOS mRNA]; KN 62 inhibits the reaction [Hemin results in increased expression of FOS mRNA]; staurosporine aglycone inhibits the reaction [Hemin results in increased expression of FOS mRNA]
|
CTD |
PMID:10381381 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
| G
|
Fosl1
|
FOS like 1, AP-1 transcription factor subunit
|
decreases expression
|
ISO
|
Hemin results in decreased expression of FOSL1 protein
|
CTD |
PMID:20006635 |
|
NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391
|
|
| G
|
Fth1
|
ferritin heavy chain 1
|
increases expression
|
EXP ISO
|
Hemin results in increased expression of FTH1 mRNA; Hemin results in increased expression of FTH1 protein
|
CTD |
PMID:15893546 PMID:16568477 PMID:17469137 PMID:29749404 PMID:31054940 |
|
NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214
|
|
| G
|
Ftl1
|
ferritin light chain 1
|
multiple interactions increases expression
|
ISO EXP
|
[Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA Hemin results in increased expression of FTL mRNA; Hemin results in increased expression of FTL1 protein Hemin results in increased expression of FTL1 mRNA
|
CTD |
PMID:12393473 PMID:15893546 PMID:16568477 PMID:29749404 |
|
NCBI chr 1:105,072,858...105,074,705
Ensembl chr X:45,399,355...45,399,915 Ensembl chr 2:45,399,355...45,399,915 Ensembl chr 1:45,399,355...45,399,915
|
|
| G
|
Gas1
|
growth arrest-specific 1
|
multiple interactions
|
ISO
|
[Hemin results in increased abundance of Iron] which results in increased expression of GAS1 mRNA
|
CTD |
PMID:12393473 |
|
NCBI chr17:4,487,716...4,490,701
Ensembl chr17:4,484,283...4,497,657
|
|
| G
|
Gata1
|
GATA binding protein 1
|
increases expression multiple interactions affects expression decreases expression
|
ISO
|
Hemin results in increased expression of GATA1 mRNA catechol promotes the reaction [Hemin results in increased expression of GATA1 mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Hemin promotes the reaction [catechol results in increased expression of GATA1 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA] Hemin affects the expression of GATA1 mRNA Hemin results in decreased expression of GATA1 protein
|
CTD |
PMID:21414390 PMID:23973255 PMID:28552822 PMID:37329354 |
|
NCBI chr X:17,193,291...17,209,462
Ensembl chr X:17,201,633...17,209,459
|
|
| G
|
Gata2
|
GATA binding protein 2
|
decreases expression multiple interactions affects expression
|
ISO
|
Hemin results in decreased expression of GATA2 mRNA; Hemin results in decreased expression of GATA2 protein hydroquinone affects the reaction [Hemin affects the expression of GATA2 mRNA]; hydroquinone inhibits the reaction [Hemin results in decreased expression of GATA2 protein]; hydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]
|
CTD |
PMID:21414390 PMID:37329354 |
|
NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:122,211,829...122,225,055
|
|
| G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
increases expression multiple interactions
|
ISO
|
Hemin results in increased expression of GCLC mRNA; Hemin results in increased expression of GCLC protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC protein
|
CTD |
PMID:16631525 PMID:33434570 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
|
|
| G
|
Gclm
|
glutamate cysteine ligase, modifier subunit
|
increases expression multiple interactions
|
ISO
|
Hemin results in increased expression of GCLM mRNA; Hemin results in increased expression of GCLM protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM protein
|
CTD |
PMID:33434570 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003
|
|
| G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions increases export
|
ISO
|
HSPA8 protein inhibits the reaction [Hemin results in increased export of GPT protein]
|
CTD |
PMID:39486598 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
| G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions increases expression
|
ISO
|
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR protein Hemin results in increased expression of GSR mRNA; Hemin results in increased expression of GSR protein
|
CTD |
PMID:33434570 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
| G
|
Gsta4
|
glutathione S-transferase alpha 4
|
increases expression
|
ISO
|
Hemin results in increased expression of GSTA4 mRNA
|
CTD |
PMID:19482077 |
|
NCBI chr 8:87,947,247...87,964,490
Ensembl chr 8:87,930,566...87,964,488
|
|
| G
|
Gsto1
|
glutathione S-transferase omega 1
|
increases expression multiple interactions
|
ISO
|
Hemin results in increased expression of GSTO1 mRNA [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSTO1 mRNA
|
CTD |
PMID:33434570 |
|
NCBI chr 1:256,662,377...256,672,515
Ensembl chr 1:256,662,531...256,676,167
|
|
| G
|
Gstp1
|
glutathione S-transferase pi 1
|
multiple interactions
|
ISO
|
Hemin results in increased stability of and results in increased expression of GSTP1 mRNA
|
CTD |
PMID:15313425 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
| G
|
Gstz1
|
glutathione S-transferase zeta 1
|
decreases activity
|
ISO
|
Hemin results in decreased activity of GSTZ1 protein
|
CTD |
PMID:1846734 |
|
NCBI chr 6:112,525,576...112,536,228
Ensembl chr 6:112,525,377...112,536,233
|
|
| G
|
Hamp
|
hepcidin antimicrobial peptide
|
increases expression decreases response to substance multiple interactions
|
ISO
|
Hemin results in increased expression of HAMP mRNA HAMP mRNA results in decreased susceptibility to Hemin [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA; [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA; HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA]; necrostatin-1 promotes the reaction [HAMP mRNA results in decreased susceptibility to Hemin]
|
CTD |
PMID:29749404 |
|
NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:95,298,307...95,300,297
|
|
| G
|
Hbb
|
hemoglobin subunit beta
|
multiple interactions increases expression
|
ISO
|
[catechol co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol promotes the reaction [Hemin results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HBB mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]; trichostatin A inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]
|
CTD |
PMID:21414390 PMID:23973255 PMID:24141029 PMID:28552822 PMID:30327826 |
|
NCBI chr 1:167,662,310...167,663,721
Ensembl chr 1:167,630,245...167,663,873
|
|
| G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
multiple interactions decreases expression
|
ISO
|
[Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA Hemin results in decreased expression of HIF1A mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA
|
CTD |
PMID:12393473 PMID:29749404 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
| G
|
Hmbs
|
hydroxymethylbilane synthase
|
multiple interactions increases expression
|
ISO
|
[catechol co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol promotes the reaction [Hemin results in increased expression of HMBS mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HMBS mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA]
|
CTD |
PMID:21414390 PMID:23973255 PMID:24141029 PMID:28552822 |
|
NCBI chr 8:53,570,364...53,577,758
Ensembl chr 8:53,570,364...53,577,802
|
|
| G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions decreases response to substance increases activity increases expression decreases expression
|
ISO EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 protein; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased activity of HMOX1 protein] which results in decreased chemical synthesis of Reactive Oxygen Species; [Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein; BACH1 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Genistein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Curcumin results in increased expression of HMOX1 mRNA]; Hemin results in increased expression of and results in increased activity of HMOX1 protein; herbimycin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein] HMOX1 protein results in decreased susceptibility to Hemin 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin co-treated with Hemin] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Hemin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [3-hydroxyflavone results in increased expression of HMOX1 protein]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; Hemin promotes the reaction [baicalein results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]; Hemin promotes the reaction [kaempferol results in increased expression of HMOX1 protein]; Hemin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Quercetin results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; Quercetin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in decreased expression of HMOX1 protein; [Hemin co-treated with Fructose] results in increased expression of HMOX1 protein; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 mRNA; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 protein; [Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in decreased expression of HMOX1 protein]; chromium mesoporphyrin inhibits the reaction [[Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 protein]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased activity of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA]; protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] Hemin results in increased expression of HMOX1 mRNA; Hemin results in increased expression of HMOX1 protein
|
CTD |
PMID:3343248 PMID:8764571 PMID:9337616 PMID:9722676 PMID:10349844 PMID:10473555 PMID:11232018 PMID:12051994 PMID:12393473 PMID:12690112 PMID:14563492 PMID:14647439 PMID:14871405 PMID:15316927 PMID:15589375 PMID:16109301 PMID:16462769 PMID:16631525 PMID:16647178 PMID:16839318 PMID:16959797 PMID:17173083 PMID:17204476 PMID:17275847 PMID:17420286 PMID:17464175 PMID:17541025 PMID:17979934 PMID:18206168 PMID:18215737 PMID:18357586 PMID:18550526 PMID:18845130 PMID:19080378 PMID:19136476 PMID:19190261 PMID:19520142 PMID:20016031 PMID:20020468 PMID:20638379 PMID:20961405 PMID:21525764 PMID:22859313 PMID:23272707 PMID:23942037 PMID:24095726 PMID:25268984 PMID:25449124 PMID:25824035 PMID:26747958 PMID:27777014 PMID:27815112 PMID:27830717 PMID:29086419 PMID:29749404 PMID:29797346 PMID:30040983 PMID:31054940 PMID:31518892 PMID:32671443 PMID:33434570 PMID:35691465 More...
|
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
| G
|
Hmox2
|
heme oxygenase 2
|
decreases response to substance
|
ISO
|
HMOX2 protein results in decreased susceptibility to Hemin
|
CTD |
PMID:15589375 PMID:16459095 |
|
NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800
|
|
| G
|
Hsf1
|
heat shock transcription factor 1
|
increases activity
|
ISO
|
Hemin results in increased activity of HSF1 protein
|
CTD |
PMID:34170685 |
|
NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665
|
|
| G
|
Hspa1l
|
heat shock protein family A (Hsp70) member 1 like
|
multiple interactions
|
ISO
|
[Hemin results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA
|
CTD |
PMID:12393473 |
|
NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,853,331...3,876,877
|
|
| G
|
Hspa8
|
heat shock protein family A (Hsp70) member 8
|
multiple interactions
|
ISO
|
HSPA8 protein inhibits the reaction [Hemin results in increased export of GPT protein]
|
CTD |
PMID:39486598 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372
|
|
| G
|
Hspa9
|
heat shock protein family A (Hsp70) member 9
|
multiple interactions
|
ISO
|
[Hemin results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA
|
CTD |
PMID:12393473 |
|
NCBI chr18:26,810,004...26,832,958
Ensembl chr18:26,804,774...26,828,398
|
|
| G
|
Hsph1
|
heat shock protein family H (Hsp110) member 1
|
multiple interactions
|
ISO
|
[Hemin results in increased abundance of Iron] which results in increased expression of HSPH1 mRNA
|
CTD |
PMID:12393473 |
|
NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891
|
|
| G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]
|
CTD |
PMID:10349844 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
| G
|
Il18
|
interleukin 18
|
multiple interactions decreases response to substance
|
ISO
|
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein]; Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased susceptibility to IL18 protein]
|
CTD |
PMID:18215737 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
| G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]
|
CTD |
PMID:35691465 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
| G
|
Il6
|
interleukin 6
|
increases expression multiple interactions
|
ISO
|
Hemin results in increased expression of IL6 mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]
|
CTD |
PMID:29749404 PMID:35691465 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
| G
|
Ins2
|
insulin 2
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [Fructose results in increased expression of INS protein]
|
CTD |
PMID:25268984 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805
|
|
| G
|
Ireb2
|
iron responsive element binding protein 2
|
multiple interactions
|
EXP
|
Hemin results in decreased expression of and results in decreased activity of IREB2 protein
|
CTD |
PMID:16568477 |
|
NCBI chr 8:64,124,152...64,207,702
Ensembl chr 8:64,154,945...64,205,520
|
|
| G
|
Ivl
|
involucrin
|
decreases expression
|
ISO
|
Hemin results in decreased expression of IVL mRNA
|
CTD |
PMID:20006635 |
|
NCBI chr 2:180,842,307...180,854,646
Ensembl chr 2:180,842,307...180,846,578
|
|
| G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions decreases expression
|
ISO EXP
|
[Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA Hemin promotes the reaction [Paraquat results in increased phosphorylation of JUN protein] Hemin results in decreased expression of JUN mRNA
|
CTD |
PMID:12393473 PMID:19080378 PMID:20016031 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
| G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
decreases expression
|
ISO
|
Hemin results in decreased expression of KEAP1 protein
|
CTD |
PMID:27777014 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
| G
|
Lox
|
lysyl oxidase
|
multiple interactions
|
ISO
|
[Hemin results in decreased abundance of Iron] which results in increased expression of LOX mRNA
|
CTD |
PMID:12393473 |
|
NCBI chr18:48,162,889...48,175,640
Ensembl chr18:48,165,688...48,239,810
|
|
| G
|
Magi1
|
membrane associated guanylate kinase, WW and PDZ domain containing 1
|
multiple interactions
|
ISO
|
[Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 mRNA; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein]
|
CTD |
PMID:32198055 |
|
NCBI chr 4:127,762,590...128,368,228
Ensembl chr 4:127,762,590...128,367,833
|
|
| G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation multiple interactions
|
ISO
|
Hemin results in increased phosphorylation of MAPK1 protein diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:16959797 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
| G
|
Mapk11
|
mitogen-activated protein kinase 11
|
multiple interactions
|
ISO
|
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein]
|
CTD |
PMID:18215737 |
|
NCBI chr 7:122,098,120...122,105,023
Ensembl chr 7:122,098,121...122,105,038
|
|
| G
|
Mapk14
|
mitogen activated protein kinase 14
|
multiple interactions
|
ISO
|
Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein]
|
CTD |
PMID:18215737 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
| G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases phosphorylation
|
ISO
|
diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:16959797 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
| G
|
Mapk8
|
mitogen-activated protein kinase 8
|
multiple interactions
|
EXP
|
Hemin promotes the reaction [Paraquat results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:19080378 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
| G
|
Mapk9
|
mitogen-activated protein kinase 9
|
multiple interactions decreases expression
|
EXP
|
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA] Hemin results in decreased expression of MAPK9 mRNA
|
CTD |
PMID:19190261 PMID:20016031 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228
|
|
| G
|
Mfn1
|
mitofusin 1
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]; Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]
|
CTD |
PMID:27830717 |
|
NCBI chr 2:117,240,525...117,288,017
Ensembl chr 2:117,241,759...117,290,190
|
|
| G
|
Mgst1
|
microsomal glutathione S-transferase 1
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [Gallic Acid results in increased activity of MGST1 protein]
|
CTD |
PMID:19111564 |
|
NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:172,760,886...172,776,875
|
|
| G
|
Mir126a
|
microRNA 126a
|
decreases expression
|
ISO
|
Hemin results in decreased expression of MIR126 mRNA
|
CTD |
PMID:28733890 |
|
NCBI chr 3:29,813,150...29,813,267
|
|
| G
|
Mir451a
|
microRNA 451a
|
increases expression multiple interactions
|
ISO
|
Hemin results in increased expression of MIR451A mRNA hydroquinone affects the reaction [Hemin results in increased expression of MIR451A mRNA]
|
CTD |
PMID:28733890 |
|
NCBI chr10:63,459,569...63,459,640
Ensembl chr10:63,459,569...63,459,640
|
|
| G
|
Mir486
|
microRNA 486
|
increases expression multiple interactions
|
ISO
|
Hemin results in increased expression of MIR486-1 mRNA [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of MIR486-1 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]
|
CTD |
PMID:32198055 |
|
|
|
| G
|
Mmp1
|
matrix metallopeptidase 1
|
increases expression
|
ISO
|
Hemin results in increased expression of MMP1 protein
|
CTD |
PMID:19136476 |
|
NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964
|
|
| G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]
|
CTD |
PMID:17979934 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
| G
|
Mt2
|
metallothionein 2
|
multiple interactions
|
ISO
|
[Hemin results in decreased abundance of Iron] which results in increased expression of MT2A mRNA
|
CTD |
PMID:12393473 |
|
NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709
|
|
| G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions
|
ISO
|
[Hemin results in increased abundance of Iron] which results in increased expression of MYC mRNA
|
CTD |
PMID:12393473 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
| G
|
Nfe2
|
nuclear factor, erythroid 2
|
increases expression multiple interactions
|
ISO
|
Hemin results in increased expression of NFE2 mRNA catechol promotes the reaction [Hemin results in increased expression of NFE2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of NFE2 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]
|
CTD |
PMID:21414390 PMID:28552822 |
|
NCBI chr 7:136,261,234...136,273,850
Ensembl chr 7:136,261,236...136,268,585
|
|
| G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions decreases expression increases expression affects localization
|
ISO EXP
|
[Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of and affects the localization of NFE2L2 protein; diacetyldichlorofluorescein inhibits the reaction [Hemin affects the localization of NFE2L2 protein]; Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; Hemin results in increased expression of and affects the localization of NFE2L2 protein; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] NFE2L2 gene mutant form inhibits the reaction [Hemin results in increased expression of CYP2A5 mRNA]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA] Hemin results in decreased expression of NFE2L2 protein [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Hemin] affects the localization of NFE2L2 protein; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]
|
CTD |
PMID:10473555 PMID:16959797 PMID:21464371 PMID:21525764 PMID:22859313 PMID:23272707 PMID:25824035 PMID:26747958 PMID:27777014 PMID:31054940 PMID:33434570 More...
|
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
| G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO EXP
|
Hemin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein]; Hemin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Hemin promotes the reaction [3-hydroxyflavone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [baicalein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 protein]
|
CTD |
PMID:14563492 PMID:15316927 PMID:26747958 PMID:27815112 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
| G
|
Nos3
|
nitric oxide synthase 3
|
multiple interactions
|
EXP
|
[Nitroglycerin co-treated with Hemin] results in increased expression of NOS3 mRNA
|
CTD |
PMID:17541025 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
| G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
increases expression multiple interactions
|
ISO
|
Hemin results in increased expression of NQO1 mRNA; Hemin results in increased expression of NQO1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 protein; Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein]
|
CTD |
PMID:21464371 PMID:31054940 PMID:33434570 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
| G
|
Nrf1
|
nuclear respiratory factor 1
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [manganese chloride affects the expression of NRF1 protein]
|
CTD |
PMID:30040983 |
|
NCBI chr 4:59,632,366...59,738,166
Ensembl chr 4:59,632,372...59,738,353
|
|
| G
|
Ogt
|
O-linked N-acetylglucosamine (GlcNAc) transferase
|
multiple interactions
|
ISO
|
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein]
|
CTD |
PMID:27231347 |
|
NCBI chr X:70,811,317...70,856,123
Ensembl chr X:70,811,319...70,856,123
|
|
| G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
Hemin results in increased expression of and results in increased cleavage of PARP1 protein
|
CTD |
PMID:39486598 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
| G
|
Pde5a
|
phosphodiesterase 5A
|
decreases expression
|
EXP
|
Hemin results in decreased expression of PDE5A protein
|
CTD |
PMID:16839318 |
|
NCBI chr 2:213,542,822...213,687,638
Ensembl chr 2:213,542,923...213,684,298
|
|
| G
|
Pdgfb
|
platelet derived growth factor subunit B
|
multiple interactions
|
ISO
|
[Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein
|
CTD |
PMID:20961405 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343
|
|
| G
|
Pdgfrb
|
platelet derived growth factor receptor beta
|
multiple interactions
|
ISO
|
[hydroquinone co-treated with Hemin] affects the expression of PDGFRB mRNA
|
CTD |
PMID:32198055 |
|
NCBI chr18:56,770,348...56,809,228
Ensembl chr18:56,770,348...56,809,233
|
|
| G
|
Pmp22
|
peripheral myelin protein 22
|
multiple interactions
|
ISO
|
[Hemin results in decreased abundance of Iron] which results in increased expression of PMP22 mRNA
|
CTD |
PMID:12393473 |
|
NCBI chr10:48,294,932...48,324,941
Ensembl chr10:48,297,437...48,324,940
|
|
| G
|
Por
|
cytochrome p450 oxidoreductase
|
multiple interactions decreases activity
|
ISO
|
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Dimethyl Sulfoxide promotes the reaction [Hemin results in decreased activity of POR protein]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin promotes the reaction [Dimethyl Sulfoxide results in decreased activity of POR protein]
|
CTD |
PMID:11368792 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809
|
|
| G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [manganese chloride affects the expression of PPARGC1A protein]
|
CTD |
PMID:30040983 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213
|
|
| G
|
Pten
|
phosphatase and tensin homolog
|
multiple interactions
|
ISO
|
Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein]
|
CTD |
PMID:18215737 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
| G
|
Ptger2
|
prostaglandin E receptor 2
|
increases response to substance
|
ISO
|
PTGER2 gene mutant form results in increased susceptibility to Hemin
|
CTD |
PMID:25451967 |
|
NCBI chr15:20,694,765...20,708,475
Ensembl chr15:20,696,013...20,708,950
|
|
| G
|
Rap1a
|
RAP1A, member of RAS oncogene family
|
multiple interactions
|
ISO
|
[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAP1A protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]
|
CTD |
PMID:32198055 |
|
NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:195,896,971...195,974,808
|
|
| G
|
Rapgef2
|
Rap guanine nucleotide exchange factor 2
|
multiple interactions
|
ISO
|
[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]
|
CTD |
PMID:32198055 |
|
NCBI chr 2:166,505,868...166,728,139
Ensembl chr 2:166,505,868...166,726,698
|
|
| G
|
Rassf5
|
Ras association domain family member 5
|
multiple interactions
|
ISO
|
[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein]
|
CTD |
PMID:32198055 |
|
NCBI chr13:45,189,768...45,255,277
Ensembl chr13:45,189,804...45,255,277
|
|
| G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions decreases expression
|
EXP
|
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA] Hemin results in decreased expression of RELA mRNA
|
CTD |
PMID:19190261 PMID:20016031 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
| G
|
Runx2
|
RUNX family transcription factor 2
|
decreases expression
|
EXP
|
Hemin results in decreased expression of RUNX2 mRNA
|
CTD |
PMID:20020468 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
| G
|
Sesn2
|
sestrin 2
|
multiple interactions affects response to substance increases expression
|
ISO
|
[SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form Hemin results in increased expression of SESN2 protein [Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; Acetylcysteine inhibits the reaction [Hemin results in increased expression of SESN2 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein]
|
CTD |
PMID:31054940 |
|
NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255
|
|
| G
|
Slc2a4
|
solute carrier family 2 member 4
|
multiple interactions
|
EXP
|
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein]]; Hemin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein]
|
CTD |
PMID:19190261 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270
|
|
| G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions
|
EXP
|
Hemin promotes the reaction [Acetaminophen results in increased expression of SOD2 protein]
|
CTD |
PMID:12051994 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
| G
|
Syn1
|
synapsin I
|
multiple interactions
|
ISO
|
Hemin inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of SYN1 protein]
|
CTD |
PMID:36096218 |
|
NCBI chr X:3,725,745...3,780,940
Ensembl chr X:3,725,714...3,780,938
|
|
| G
|
Tfap2c
|
transcription factor AP-2 gamma
|
decreases expression
|
EXP
|
Hemin results in decreased expression of TFAP2C mRNA
|
CTD |
PMID:20016031 |
|
NCBI chr 3:181,733,524...181,742,412
Ensembl chr 3:181,733,419...181,741,404
|
|
| G
|
Tfrc
|
transferrin receptor
|
decreases expression multiple interactions
|
EXP ISO
|
Hemin results in decreased expression of TFRC protein [Hemin results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; hydroquinone promotes the reaction [Hemin results in decreased expression of TFRC mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of TFRC mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of TFRC mRNA] Hemin results in decreased expression of TFRC mRNA; Hemin results in decreased expression of TFRC protein
|
CTD |
PMID:12393473 PMID:16568477 PMID:16760464 PMID:21414390 PMID:25576684 |
|
NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318
|
|
| G
|
Tgm2
|
transglutaminase 2
|
multiple interactions
|
ISO
|
[Hemin co-treated with Tretinoin] affects the localization of TGM2 protein
|
CTD |
PMID:15556610 |
|
NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:167,192,612...167,304,240
|
|
| G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
EXP ISO
|
[Hemin co-treated with indole-3-carbinol co-treated with 1,2-Dimethylhydrazine] affects the expression of TNF mRNA; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of TNF protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased expression of TNF]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Hemin inhibits the reaction [Cisplatin results in increased expression of TNF protein]
|
CTD |
PMID:17173083 PMID:19150641 PMID:26747958 PMID:27815112 PMID:29269057 PMID:35691465 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tnfrsf10b
|
TNF receptor superfamily member 10b
|
increases expression
|
ISO
|
Hemin results in increased expression of TNFRSF10A protein
|
CTD |
PMID:39486598 |
|
NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082
|
|
| G
|
Tnfrsf1a
|
TNF receptor superfamily member 1A
|
increases expression
|
ISO
|
Hemin results in increased expression of TNFRSF1A protein
|
CTD |
PMID:39486598 |
|
NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816
|
|
| G
|
Tnfrsf1b
|
TNF receptor superfamily member 1B
|
increases expression
|
ISO
|
Hemin results in increased expression of TNFRSF1B protein
|
CTD |
PMID:39486598 |
|
NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:162,353,848...162,387,411
|
|
| G
|
Tnfrsf25
|
TNF receptor superfamily member 25
|
increases expression
|
ISO
|
Hemin results in increased expression of TNFRSF25 protein
|
CTD |
PMID:39486598 |
|
NCBI chr 5:167,904,377...167,909,052
Ensembl chr 5:167,904,786...167,909,052
|
|
| G
|
Ulk1
|
unc-51 like autophagy activating kinase 1
|
increases expression
|
ISO
|
Hemin results in increased expression of ATG1 protein
|
CTD |
PMID:39486598 |
|
NCBI chr12:51,511,492...51,537,746
Ensembl chr12:51,511,492...51,537,746
|
|
| G
|
Vasp
|
vasodilator-stimulated phosphoprotein
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [Nitroglycerin results in decreased phosphorylation of VASP protein]
|
CTD |
PMID:17541025 |
|
NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650
|
|
| G
|
Xbp1
|
X-box binding protein 1
|
increases splicing
|
ISO
|
Hemin results in increased splicing of XBP1 mRNA
|
CTD |
PMID:35341795 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706
|
|
| G
|
Zfp36
|
zinc finger protein 36
|
multiple interactions increases expression
|
ISO
|
zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of ZFP36 mRNA]
|
CTD |
PMID:24095726 |
|
NCBI chr 1:92,796,628...92,799,108
Ensembl chr 1:92,796,628...92,799,108
|
|
|
|
| G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]] zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
|
CTD |
PMID:20052772 PMID:20861358 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169
|
|
| G
|
Agt
|
angiotensinogen
|
multiple interactions
|
ISO
|
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]]
|
CTD |
PMID:20523338 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944
|
|
| G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [olprinone results in increased activity of AKT1 protein]
|
CTD |
PMID:19387321 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
| G
|
Alad
|
aminolevulinate dehydratase
|
affects abundance
|
ISO
|
ALAD gene SNP affects the abundance of zinc protoporphyrin
|
CTD |
PMID:25963508 |
|
NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:80,977,562...80,988,041
|
|
| G
|
Alb
|
albumin
|
multiple interactions
|
ISO
|
ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin results in increased expression of HMOX1 protein] zinc protoporphyrin inhibits the reaction [ALB protein results in increased expression of HMOX1 protein]; zinc protoporphyrin promotes the reaction [ALB protein results in increased expression of TIMP1 protein]
|
CTD |
PMID:19376148 PMID:21163135 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
| G
|
Alms1
|
ALMS1, centrosome and basal body associated protein
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ALMS1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 4:119,683,085...119,783,471
Ensembl chr 4:119,683,076...119,783,471
|
|
| G
|
Ap2a1
|
adaptor related protein complex 2 subunit alpha 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of AP2A1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 1:104,520,789...104,550,655
Ensembl chr 1:104,520,792...104,550,655
|
|
| G
|
Ap3d1
|
adaptor related protein complex 3 subunit delta 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of AP3D1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 7:9,620,909...9,656,350
Ensembl chr 7:9,620,968...9,656,342
|
|
| G
|
Asf1a
|
anti-silencing function 1A histone chaperone
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of ASF1A mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr20:33,436,632...33,451,478
Ensembl chr20:33,436,707...33,449,639
|
|
| G
|
Bach1
|
BTB domain and CNC homolog 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in decreased expression of NFE2L2 mRNA]]; zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]]; zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in increased expression of PTGS2 mRNA]]; zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in increased expression of PTGS2 protein]]
|
CTD |
PMID:38573338 |
|
NCBI chr11:40,425,721...40,461,118
Ensembl chr11:40,425,664...40,461,277
|
|
| G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of BAX protein]] zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of BAX mRNA]] zinc protoporphyrin inhibits the reaction [Cisplatin results in increased expression of BAX protein]
|
CTD |
PMID:22763982 PMID:27523796 PMID:27815112 PMID:32621855 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
| G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]] zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]]
|
CTD |
PMID:22763982 PMID:27523796 PMID:32621855 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
| G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions increases expression
|
EXP ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of BCL2L1 protein] zinc protoporphyrin results in increased expression of BCL2L1 protein
|
CTD |
PMID:20357190 PMID:27829220 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
| G
|
Bcl2l11
|
Bcl2-like 11
|
increases expression
|
ISO
|
zinc protoporphyrin results in increased expression of BCL2L11 protein
|
CTD |
PMID:27829220 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695
|
|
| G
|
Bglap
|
bone gamma-carboxyglutamate protein
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [15-deoxyprostaglandin J2 results in decreased expression of BGLAP mRNA]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased expression of BGLAP mRNA]
|
CTD |
PMID:20020468 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318
|
|
| G
|
Birc3
|
baculoviral IAP repeat-containing 3
|
multiple interactions
|
ISO
|
zinc protoporphyrin analog inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of BIRC3 protein]
|
CTD |
PMID:18508827 |
|
NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590
|
|
| G
|
Calca
|
calcitonin-related polypeptide alpha
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [monophosphoryl lipid A results in increased expression of CALCA mRNA]
|
CTD |
PMID:11738242 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529
|
|
| G
|
Cand1
|
cullin-associated and neddylation-dissociated 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CAND1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 7:56,566,765...56,604,653
Ensembl chr 7:56,551,394...56,604,655
|
|
| G
|
Casp1
|
caspase 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of CASP1 protein]]
|
CTD |
PMID:36858639 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
| G
|
Casp3
|
caspase 3
|
multiple interactions increases cleavage decreases activity
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]; zinc protoporphyrin promotes the reaction [T-2 Toxin results in increased activity of CASP3 protein] zinc protoporphyrin results in increased cleavage of CASP3 protein zinc protoporphyrin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased activity of CASP3 protein]]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; zinc protoporphyrin promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]; zinc protoporphyrin promotes the reaction [quinocetone results in increased activity of CASP3 protein] zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of CASP3 mRNA]]; zinc protoporphyrin promotes the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased cleavage of CASP3 protein]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased cleavage of CASP3 protein] zinc protoporphyrin results in decreased activity of CASP3 protein
|
CTD |
PMID:16051694 PMID:17928392 PMID:20357190 PMID:21295052 PMID:22763982 PMID:25003661 PMID:26747958 PMID:27375190 PMID:27815112 PMID:28025122 PMID:29432840 PMID:30261164 PMID:32621855 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
| G
|
Casp8
|
caspase 8
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP8 protein]
|
CTD |
PMID:16051694 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
| G
|
Casp9
|
caspase 9
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased activity of CASP9 protein]]; zinc protoporphyrin promotes the reaction [quinocetone results in increased activity of CASP9 protein] zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein]]; zinc protoporphyrin promotes the reaction [T-2 Toxin results in increased activity of CASP9 protein]
|
CTD |
PMID:27375190 PMID:29432840 PMID:30261164 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
| G
|
Cat
|
catalase
|
multiple interactions
|
EXP ISO
|
zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in decreased expression of CAT protein]] zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]]
|
CTD |
PMID:32621855 PMID:35691465 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
| G
|
Ccdc6
|
coiled-coil domain containing 6
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of CCDC6 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr20:18,431,243...18,527,227
Ensembl chr20:18,431,243...18,527,227
|
|
| G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions
|
EXP ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of CCL2 protein]; zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of CCL2 mRNA] zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]]
|
CTD |
PMID:20357190 PMID:23892052 PMID:35691465 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
| G
|
Ccr7
|
C-C motif chemokine receptor 7
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CCR7 mRNA]
|
CTD |
PMID:33049506 |
|
NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,593,594...84,604,501
|
|
| G
|
Cd40
|
CD40 molecule
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]
|
CTD |
PMID:33049506 |
|
NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847
|
|
| G
|
Cd80
|
Cd80 molecule
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 mRNA]
|
CTD |
PMID:33049506 |
|
NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540
|
|
| G
|
Cd83
|
CD83 molecule
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD83 mRNA]
|
CTD |
PMID:33049506 |
|
NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047
|
|
| G
|
Cd86
|
CD86 molecule
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 mRNA]
|
CTD |
PMID:33049506 |
|
NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361
|
|
| G
|
Cdk13
|
cyclin-dependent kinase 13
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CDK13 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr17:51,945,975...52,040,218
Ensembl chr17:51,946,701...52,037,257
|
|
| G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions
|
ISO
|
zinc protoporphyrin analog inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of and affects the localization of CDKN1A protein]
|
CTD |
PMID:18508827 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
| G
|
Chd7
|
chromodomain helicase DNA binding protein 7
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CHD7 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 5:26,609,245...26,792,736
Ensembl chr 5:26,609,407...26,792,734
|
|
| G
|
Cmbl
|
carboxymethylenebutenolidase homolog
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CMBL mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:84,242,512...84,301,880
|
|
| G
|
Cxcl1
|
C-X-C motif chemokine ligand 1
|
increases expression
|
EXP
|
zinc protoporphyrin results in increased expression of CXCL1 mRNA
|
CTD |
PMID:25780291 |
|
NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811
|
|
| G
|
Cxcl10
|
C-X-C motif chemokine ligand 10
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]
|
CTD |
PMID:20861358 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261
|
|
| G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
increases expression
|
EXP
|
zinc protoporphyrin results in increased expression of CXCL2 mRNA
|
CTD |
PMID:25780291 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
| G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
EXP
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP1A1 protein
|
CTD |
PMID:26747958 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
| G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions
|
EXP
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP1A2 protein
|
CTD |
PMID:26747958 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
| G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
multiple interactions
|
EXP
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP2B1 protein
|
CTD |
PMID:26747958 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
| G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions
|
EXP ISO
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP2E1 mRNA; [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP2E1 protein; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 mRNA]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 protein] zinc protoporphyrin inhibits the reaction [Quercetin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein]]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [Ethanol results in increased activity of CYP2E1 protein]]
|
CTD |
PMID:19325051 PMID:26747958 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
| G
|
Dcun1d1
|
defective in cullin neddylation 1 domain containing 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of DCUN1D1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:120,649,445...120,700,879
Ensembl chr 2:120,649,445...120,700,870
|
|
| G
|
Ddit3
|
DNA-damage inducible transcript 3
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of DDIT3 protein]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of DDIT3 protein]
|
CTD |
PMID:26747958 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
| G
|
Dhx29
|
DExH-box helicase 29
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of DHX29 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:46,293,901...46,344,652
Ensembl chr 2:46,293,677...46,344,948
|
|
| G
|
Dusp10
|
dual specificity phosphatase 10
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [andrographolide results in increased expression of DUSP10 mRNA]; zinc protoporphyrin inhibits the reaction [andrographolide results in increased expression of DUSP10 protein]
|
CTD |
PMID:29165873 |
|
NCBI chr13:98,145,317...98,183,304
Ensembl chr13:98,145,893...98,183,304
|
|
| G
|
Eif2ak3
|
eukaryotic translation initiation factor 2 alpha kinase 3
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased phosphorylation of EIF2AK3 protein]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased phosphorylation of EIF2AK3 protein]
|
CTD |
PMID:26747958 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268
|
|
| G
|
Eml4
|
EMAP like 4
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of EML4 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:16,972,054...17,087,365
Ensembl chr 6:16,972,075...17,087,439
|
|
| G
|
F2
|
coagulation factor II, thrombin
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased expression of PTGS2 protein]]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased secretion of Dinoprostone]]
|
CTD |
PMID:26385185 |
|
NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246
|
|
| G
|
Faslg
|
Fas ligand
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP8 protein]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased cleavage of CASP3 protein]
|
CTD |
PMID:16051694 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
| G
|
Fbxw12
|
F-box and WD repeat domain containing 12
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of FBXW12 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 8:118,660,777...118,680,565
Ensembl chr 8:118,660,605...118,680,572
|
|
| G
|
Fgfr1
|
Fibroblast growth factor receptor 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of FGFR1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855
|
|
| G
|
Flt1
|
Fms related receptor tyrosine kinase 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]
|
CTD |
PMID:25371888 |
|
NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750
|
|
| G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
increases expression
|
ISO
|
zinc protoporphyrin results in increased expression of FOS mRNA
|
CTD |
PMID:10381381 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
| G
|
Fut4
|
fucosyltransferase 4
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of FUT4 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 8:19,868,178...19,872,139
Ensembl chr 8:19,868,079...19,872,436
|
|
| G
|
Glul
|
glutamate-ammonia ligase
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Ammonia results in decreased activity of GLUL protein]]; zinc protoporphyrin inhibits the reaction [Resveratrol results in increased activity of GLUL protein]
|
CTD |
PMID:26318273 |
|
NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520
|
|
| G
|
Gpr132
|
G protein-coupled receptor 132
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of GPR132 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:137,745,142...137,763,037
Ensembl chr 6:137,745,241...137,763,157
|
|
| G
|
Gpx1
|
glutathione peroxidase 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of GPX1 protein]
|
CTD |
PMID:36696656 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
| G
|
Gpx4
|
glutathione peroxidase 4
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of GPX4 protein] zinc protoporphyrin inhibits the reaction [Cadmium results in decreased expression of GPX4 protein]
|
CTD |
PMID:36696656 PMID:39025289 |
|
NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629
|
|
| G
|
Gsdmd
|
gasdermin D
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of GSDMD protein]]
|
CTD |
PMID:36858639 |
|
NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:109,422,910...109,430,722
|
|
| G
|
Gucy1a1
|
guanylate cyclase 1 soluble subunit alpha 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
|
CTD |
PMID:19466990 |
|
NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737
|
|
| G
|
Gucy1b1
|
guanylate cyclase 1 soluble subunit beta 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
|
CTD |
PMID:19466990 |
|
NCBI chr 2:169,646,897...169,697,060
Ensembl chr 2:169,646,898...169,696,987
|
|
| G
|
Haus2
|
HAUS augmin like complex subunit 2
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of HAUS2 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 3:128,006,894...128,019,730
Ensembl chr 3:128,006,932...128,019,729
|
|
| G
|
Havcr1
|
hepatitis A virus cellular receptor 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [Cadmium results in increased expression of HAVCR1 protein]
|
CTD |
PMID:39025289 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268
|
|
| G
|
Hfe
|
homeostatic iron regulator
|
affects abundance
|
ISO
|
HFE gene polymorphism affects the abundance of zinc protoporphyrin
|
CTD |
PMID:25963508 |
|
NCBI chr17:41,841,302...41,849,359
Ensembl chr17:41,841,252...41,851,208
|
|
| G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [HIF1A protein results in increased activity of SOD2 protein]
|
CTD |
PMID:17066447 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
| G
|
Hmgb1
|
high mobility group box 1
|
multiple interactions
|
EXP ISO
|
zinc protoporphyrin promotes the reaction [lead acetate results in increased expression of HMGB1 mRNA] zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased expression of HMGB1 protein]]
|
CTD |
PMID:29447957 PMID:30261164 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327 Ensembl chr12:39,039,050...39,041,327
|
|
| G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions decreases expression increases expression affects expression decreases activity
|
ISO EXP
|
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [cobaltiprotoporphyrin results in increased expression of TP53 protein]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] which results in increased susceptibility to 2-butenal; [zinc protoporphyrin results in decreased activity of HMOX1 protein] which results in increased susceptibility to Arsenic Trioxide; [zinc protoporphyrin results in decreased activity of HMOX1] which results in decreased susceptibility to peoniflorin; zinc protoporphyrin analog inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron]; zinc protoporphyrin inhibits the reaction [[cobaltiprotoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Ethanol results in decreased abundance of Glutathione]]; zinc protoporphyrin inhibits the reaction [[cobaltiprotoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Ethanol results in increased abundance of Malondialdehyde]]; zinc protoporphyrin inhibits the reaction [[cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in decreased susceptibility to Ethanol]; zinc protoporphyrin inhibits the reaction [ALB protein results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Cilostazol results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Cilostazol results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased activity of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine promotes the reaction [Ropivacaine results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of HMOX1 protein]; zinc protoporphyrin promotes the reaction [Arsenic Trioxide results in increased expression of HMOX1 protein]; zinc protoporphyrin results in decreased expression of and results in decreased activity of HMOX1 protein; zinc protoporphyrin results in increased expression of and results in decreased activity of HMOX1 protein zinc protoporphyrin results in decreased expression of HMOX1 mRNA; zinc protoporphyrin results in decreased expression of HMOX1 protein zinc protoporphyrin results in increased expression of HMOX1 protein zinc protoporphyrin affects the expression of HMOX1 mRNA; zinc protoporphyrin affects the expression of HMOX1 protein zinc protoporphyrin results in decreased activity of HMOX1; zinc protoporphyrin results in decreased activity of HMOX1 protein zinc protoporphyrin results in increased expression of HMOX1 mRNA; zinc protoporphyrin results in increased expression of HMOX1 protein [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of HMOX1 mRNA; [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with zinc protoporphyrin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [Resveratrol results in increased abundance of Glutathione]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] which results in decreased susceptibility to Resveratrol; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Cadmium results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin promotes the reaction [Glucose results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; zinc protoporphyrin inhibits the reaction [lead acetate results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [olprinone results in increased activity of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [perflexane promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of and results in increased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Propofol inhibits the reaction [Glucose results in decreased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Propofol promotes the reaction [Glucose results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Sildenafil Citrate results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Sildenafil Citrate results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of HMOX1 protein] [zinc protoporphyrin co-treated with Hemin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; ALB protein inhibits the reaction [zinc protoporphyrin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone] results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Cisplatin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of HMOX1 protein]]
|
CTD |
PMID:7524564 PMID:12352873 PMID:14649057 PMID:15602829 PMID:16462769 PMID:17292349 PMID:17627722 PMID:17928392 PMID:18006204 PMID:18042465 PMID:18073186 PMID:18508827 PMID:19019021 PMID:19136476 PMID:19376148 PMID:19387321 PMID:19608869 PMID:20052772 PMID:20056245 PMID:20131233 PMID:20357190 PMID:20360627 PMID:20523338 PMID:21163135 PMID:21238556 PMID:21253390 PMID:21295052 PMID:21315065 PMID:21327864 PMID:21382476 PMID:21448202 PMID:21518603 PMID:21660147 PMID:21690482 PMID:21925249 PMID:22118543 PMID:22763982 PMID:22859313 PMID:22864849 PMID:23403272 PMID:23525258 PMID:23691207 PMID:23704825 PMID:24003391 PMID:24810525 PMID:25780291 PMID:25824035 PMID:26747958 PMID:27523796 PMID:27815112 PMID:27829220 PMID:27830717 PMID:29447957 PMID:31356851 PMID:32621855 PMID:33049506 PMID:34029560 PMID:35691465 PMID:36696656 PMID:36858639 PMID:39025289 More...
|
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
| G
|
Hmox2
|
heme oxygenase 2
|
decreases activity decreases expression
|
ISO EXP
|
zinc protoporphyrin results in decreased activity of HMOX2 protein zinc protoporphyrin results in decreased expression of HMOX2 protein
|
CTD |
PMID:21448202 PMID:25824035 |
|
NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800
|
|
| G
|
Hp1bp3
|
heterochromatin protein 1, binding protein 3
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of HP1BP3 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 5:155,719,109...155,746,329
Ensembl chr 5:155,719,115...155,746,325
|
|
| G
|
Hsd11b1
|
hydroxysteroid 11-beta dehydrogenase 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of HSD11B1 mRNA]]
|
CTD |
PMID:27523796 |
|
NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432
|
|
| G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of ICAM1 mRNA] zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]
|
CTD |
PMID:19608869 PMID:23892052 PMID:33049506 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
| G
|
Ifnb1
|
interferon beta 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]]
|
CTD |
PMID:20861358 |
|
NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487
|
|
| G
|
Ifng
|
interferon gamma
|
multiple interactions increases expression
|
EXP
|
zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased expression of HMOX1 protein] zinc protoporphyrin results in increased expression of IFNG mRNA
|
CTD |
PMID:21295052 PMID:25780291 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
| G
|
Il10
|
interleukin 10
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of IL10 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of IL10 protein]; zinc protoporphyrin inhibits the reaction [perflexane inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of IL10 protein]]
|
CTD |
PMID:20056245 PMID:20360627 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
| G
|
Il12b
|
interleukin 12B
|
multiple interactions
|
ISO
|
zinc protoporphyrin promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]]
|
CTD |
PMID:33049506 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
| G
|
Il18
|
interleukin 18
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL18 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased susceptibility to IL18 protein]
|
CTD |
PMID:18215737 PMID:36858639 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
| G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [Cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL1B protein]] zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]] zinc protoporphyrin results in increased expression of IL1B mRNA zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased expression of HMOX1 protein]; zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of IL1B mRNA]
|
CTD |
PMID:20131233 PMID:21295052 PMID:23892052 PMID:25780291 PMID:27523796 PMID:30261164 PMID:35691465 PMID:36858639 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
| G
|
Il23a
|
interleukin 23 subunit alpha
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of IL23A mRNA]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL23A protein]]
|
CTD |
PMID:33049506 |
|
NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:1,306,320...1,308,434
|
|
| G
|
Il6
|
interleukin 6
|
multiple interactions increases expression
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of IL6 protein]] zinc protoporphyrin results in increased expression of IL6 mRNA zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; zinc protoporphyrin inhibits the reaction [manganese chloride promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]
|
CTD |
PMID:19608869 PMID:20131233 PMID:21963524 PMID:25780291 PMID:27523796 PMID:30261164 PMID:33049506 PMID:35691465 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
| G
|
Inpp5d
|
inositol polyphosphate-5-phosphatase D
|
decreases expression
|
EXP
|
zinc protoporphyrin results in decreased expression of INPP5D protein
|
CTD |
PMID:25780291 |
|
NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:95,735,530...95,840,589
|
|
| G
|
Irak1
|
interleukin-1 receptor-associated kinase 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [IRAK1 protein binds to MYD88 protein]
|
CTD |
PMID:25780291 |
|
NCBI chr X:156,919,927...156,929,825
Ensembl chr X:156,920,081...156,929,825
|
|
| G
|
Irak3
|
interleukin-1 receptor-associated kinase 3
|
decreases expression
|
EXP
|
zinc protoporphyrin results in decreased expression of IRAK3 protein
|
CTD |
PMID:25780291 |
|
NCBI chr 7:57,538,522...57,600,166
Ensembl chr 7:57,539,557...57,598,706
|
|
| G
|
Itgam
|
integrin subunit alpha M
|
increases expression
|
ISO
|
zinc protoporphyrin results in increased expression of ITGAM protein
|
CTD |
PMID:22118543 |
|
NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943
|
|
| G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression
|
ISO
|
zinc protoporphyrin promotes the reaction [arsenic trioxide results in increased expression of JUN protein] zinc protoporphyrin results in increased expression of JUN protein
|
CTD |
PMID:27829220 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
| G
|
Kcnab1
|
potassium voltage-gated channel subfamily A regulatory beta subunit 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KCNAB1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:151,446,975...151,913,636
Ensembl chr 2:151,446,947...151,913,636
|
|
| G
|
Kctd20
|
potassium channel tetramerization domain containing 20
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KCTD20 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr20:7,017,480...7,034,440
Ensembl chr20:7,017,502...7,034,441
|
|
| G
|
Kidins220
|
kinase D-interacting substrate 220
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of KIDINS220 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:47,346,790...47,435,599
Ensembl chr 6:47,346,832...47,431,865
|
|
| G
|
Kitlg
|
KIT ligand
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KITLG mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793
|
|
| G
|
Kras
|
KRAS proto-oncogene, GTPase
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KRAS mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320
|
|
| G
|
Larp1b
|
La ribonucleoprotein 1B
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LARP1B mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:125,860,935...125,897,189
Ensembl chr 2:125,863,997...125,897,189
|
|
| G
|
Lcn2
|
lipocalin 2
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [Cadmium results in increased expression of LCN2 protein]
|
CTD |
PMID:39025289 |
|
NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842
|
|
| G
|
Ldha
|
lactate dehydrogenase A
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of LDHA protein]]
|
CTD |
PMID:36858639 |
|
NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521
|
|
| G
|
Lnx1
|
ligand of numb-protein X 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LNX1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr14:33,868,517...33,971,217
Ensembl chr14:33,868,571...33,971,217
|
|
| G
|
Lyrm7
|
LYR motif containing 7
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LYRM7 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr10:39,465,019...39,483,973
Ensembl chr10:39,465,036...39,484,240
|
|
| G
|
Macf1
|
microtubule-actin crosslinking factor 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MACF1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 5:140,908,829...141,234,127
Ensembl chr 5:140,908,837...141,233,890
|
|
| G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation
|
ISO
|
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]] zinc protoporphyrin results in increased phosphorylation of MAPK1 protein zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; zinc protoporphyrin promotes the reaction [lipoteichoic acid results in increased phosphorylation of MAPK1 protein]; zinc protoporphyrin promotes the reaction [Peptidoglycan results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:19376148 PMID:20523338 PMID:27523796 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
| G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases phosphorylation
|
ISO
|
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]] zinc protoporphyrin results in increased phosphorylation of MAPK3 protein zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; zinc protoporphyrin promotes the reaction [lipoteichoic acid results in increased phosphorylation of MAPK3 protein]; zinc protoporphyrin promotes the reaction [Peptidoglycan results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:19376148 PMID:20523338 PMID:27523796 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
| G
|
Mark2
|
microtubule affinity regulating kinase 2
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MARK2 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 1:213,890,213...213,955,417
Ensembl chr 1:213,890,213...213,955,149
|
|
| G
|
Mfn1
|
mitofusin 1
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]
|
CTD |
PMID:27830717 |
|
NCBI chr 2:117,240,525...117,288,017
Ensembl chr 2:117,241,759...117,290,190
|
|
| G
|
Mllt3
|
MLLT3, super elongation complex subunit
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MLLT3 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 5:107,305,008...107,561,352
Ensembl chr 5:107,284,766...107,561,352
|
|
| G
|
Mmp2
|
matrix metallopeptidase 2
|
affects expression multiple interactions
|
EXP ISO
|
zinc protoporphyrin affects the expression of MMP2 zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP2 mRNA]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP2 protein]
|
CTD |
PMID:23704825 PMID:30076913 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
| G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
zinc protoporphyrin promotes the reaction [arsenic trioxide results in increased expression of MMP9 protein] zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP9 mRNA]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP9 protein]
|
CTD |
PMID:27829220 PMID:30076913 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
| G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [perflexane inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased activity of MPO protein]]; zinc protoporphyrin promotes the reaction [Indomethacin results in increased activity of MPO protein]; zinc protoporphyrin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
|
CTD |
PMID:17292349 PMID:20360627 PMID:23892052 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
| G
|
Myd88
|
MYD88, innate immune signal transduction adaptor
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [IRAK1 protein binds to MYD88 protein]; zinc protoporphyrin promotes the reaction [TLR2 protein binds to MYD88 protein]; zinc protoporphyrin promotes the reaction [TLR4 protein binds to MYD88 protein]; zinc protoporphyrin promotes the reaction [TRAF6 protein binds to MYD88 protein]
|
CTD |
PMID:25780291 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230
|
|
| G
|
Ncf1
|
neutrophil cytosolic factor 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to NCF1 protein]]]
|
CTD |
PMID:19608869 |
|
NCBI chr12:28,121,816...28,131,080
Ensembl chr12:28,121,366...28,131,079
|
|
| G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions affects expression
|
EXP
|
zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in decreased expression of NFE2L2 mRNA]]; zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] zinc protoporphyrin affects the expression of NFE2L2 mRNA; zinc protoporphyrin affects the expression of NFE2L2 protein
|
CTD |
PMID:23704825 PMID:25824035 PMID:38573338 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
| G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]
|
CTD |
PMID:21925249 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
| G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [cilostazol results in increased expression of NFKBIA protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of NFKBIA protein] zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]]
|
CTD |
PMID:20131233 PMID:21925249 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
| G
|
Nos1
|
nitric oxide synthase 1
|
multiple interactions
|
EXP
|
[Sildenafil Citrate co-treated with zinc protoporphyrin] results in increased expression of NOS1 mRNA
|
CTD |
PMID:17627722 |
|
NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837
|
|
| G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO EXP
|
[zinc protoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of NOS2 mRNA; [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of NOS2 protein; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of NOS2 mRNA]]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [Ethanol results in increased expression of NOS2 mRNA]]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 mRNA]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 protein]
|
CTD |
PMID:19376148 PMID:20357190 PMID:21925249 PMID:26460608 PMID:26747958 PMID:32621855 More...
|
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
| G
|
Pde4dip
|
phosphodiesterase 4D interacting protein
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PDE4DIP mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:187,982,002...188,178,937
Ensembl chr 2:187,981,878...188,178,869
|
|
| G
|
Pgf
|
placental growth factor
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PGF mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:110,547,165...110,557,747
Ensembl chr 6:110,547,153...110,557,747
|
|
| G
|
Polr3k
|
RNA polymerase III subunit K
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of POLR3K mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 3:189,360,349...189,364,546
Ensembl chr 3:189,360,171...189,366,697
|
|
| G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [cilostazol results in increased activity of PPARG protein]; zinc protoporphyrin inhibits the reaction [rosiglitazone results in increased activity of PPARG protein]
|
CTD |
PMID:21660147 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
| G
|
Ppil1
|
peptidylprolyl isomerase like 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of PPIL1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr20:7,303,919...7,323,962
Ensembl chr20:7,303,922...7,318,781
|
|
| G
|
Prdx2
|
peroxiredoxin 2
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PRDX2 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006
|
|
| G
|
Prr11
|
proline rich 11
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PRR11 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr10:72,396,127...72,440,643
Ensembl chr10:72,398,667...72,418,275
|
|
| G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased expression of PTGS2 protein]]; zinc protoporphyrin promotes the reaction [Arsenic Trioxide results in increased expression of PTGS2] zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in increased expression of PTGS2 mRNA]]; zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in increased expression of PTGS2 protein]]; zinc protoporphyrin inhibits the reaction [Cadmium results in increased expression of PTGS2 protein] zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
|
CTD |
PMID:23649692 PMID:24003391 PMID:26385185 PMID:30261164 PMID:38573338 PMID:39025289 More...
|
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
| G
|
Ptpn12
|
protein tyrosine phosphatase, non-receptor type 12
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of PTPN12 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 4:14,913,071...14,985,084
Ensembl chr 4:14,913,218...14,985,284
|
|
| G
|
Ptpro
|
protein tyrosine phosphatase, receptor type, O
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PTPRO mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 4:171,895,104...172,105,911
Ensembl chr 4:171,895,232...172,105,903
|
|
| G
|
Rap2c
|
RAP2C, member of RAS oncogene family
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of RAP2C mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr X:135,388,881...135,401,998
Ensembl chr X:135,388,882...135,401,998
|
|
| G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased expression of RELA mRNA]]; zinc protoporphyrin promotes the reaction [quinocetone results in increased expression of RELA mRNA] zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of RELA protein] zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased localization of and results in increased activity of RELA protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]]
|
CTD |
PMID:19608869 PMID:20131233 PMID:20357190 PMID:21925249 PMID:27375190 PMID:27523796 More...
|
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
| G
|
Rgcc
|
regulator of cell cycle
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of RGCC mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr15:61,071,574...61,084,408
Ensembl chr15:61,071,574...61,084,408
|
|
| G
|
Scaf11
|
SR-related CTD-associated factor 11
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SCAF11 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 7:129,450,872...129,503,280
Ensembl chr 7:129,417,955...129,503,280
|
|
| G
|
Scamp1
|
secretory carrier membrane protein 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SCAMP1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:27,168,863...27,251,637
Ensembl chr 2:27,168,864...27,251,742
|
|
| G
|
Sec23b
|
Sec23 homolog B, COPII coat complex component
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SEC23B mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 3:152,392,340...152,434,813
Ensembl chr 3:152,392,308...152,434,800
|
|
| G
|
Sel1l
|
SEL1L adaptor subunit of SYVN1 ubiquitin ligase
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SEL1L mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:116,466,163...116,510,436
Ensembl chr 6:116,466,163...116,510,578
|
|
| G
|
Sirt1
|
sirtuin 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Fenofibrate results in increased expression of SIRT1 protein]
|
CTD |
PMID:34520103 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
| G
|
Slc22a3
|
solute carrier family 22 member 3
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SLC22A3 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 1:50,783,218...50,872,358
Ensembl chr 1:50,783,218...50,872,353
|
|
| G
|
Slc35e1
|
solute carrier family 35, member E1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SLC35E1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr16:17,384,980...17,398,227
Ensembl chr16:17,385,030...17,397,310
|
|
| G
|
Smcr8
|
SMCR8-C9orf72 complex subunit
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SMCR8 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr10:45,957,146...45,968,388
Ensembl chr10:45,957,104...45,968,389
|
|
| G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SOD2 mRNA; zinc protoporphyrin inhibits the reaction [HIF1A protein results in increased activity of SOD2 protein]
|
CTD |
PMID:17066447 PMID:22839698 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
| G
|
Sptbn1
|
spectrin, beta, non-erythrocytic 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SPTBN1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr14:108,042,629...108,217,884
Ensembl chr14:108,042,629...108,217,836
|
|
| G
|
Src
|
SRC proto-oncogene, non-receptor tyrosine kinase
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to NCF1 protein]]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to TNFRSF1A protein]]]
|
CTD |
PMID:19608869 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462
|
|
| G
|
Ssbp3
|
single stranded DNA binding protein 3
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SSBP3 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 5:126,920,145...127,057,968
Ensembl chr 5:126,919,120...127,056,799
|
|
| G
|
St3gal1
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ST3GAL1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 7:100,734,300...100,802,443
Ensembl chr 7:100,734,300...100,745,242
|
|
| G
|
Stat1
|
signal transducer and activator of transcription 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Ozone results in increased phosphorylation of STAT1 protein]
|
CTD |
PMID:19061877 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346
|
|
| G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions
|
EXP ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]]; zinc protoporphyrin inhibits the reaction [Propofol inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]] zinc protoporphyrin inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]
|
CTD |
PMID:24095726 PMID:24810525 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
| G
|
Tgfb1
|
transforming growth factor, beta 1
|
affects expression decreases secretion increases expression
|
EXP
|
zinc protoporphyrin affects the expression of TGFB1 zinc protoporphyrin results in decreased secretion of TGFB1 protein zinc protoporphyrin results in increased expression of TGFB1 protein
|
CTD |
PMID:21163135 PMID:23525258 PMID:23704825 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
| G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
affects expression multiple interactions
|
EXP ISO
|
zinc protoporphyrin affects the expression of TIMP1 zinc protoporphyrin promotes the reaction [ALB protein results in increased expression of TIMP1 protein]
|
CTD |
PMID:21163135 PMID:23704825 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
| G
|
Tlr2
|
toll-like receptor 2
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [TLR2 protein binds to MYD88 protein]
|
CTD |
PMID:25780291 |
|
NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194
|
|
| G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [TLR4 protein binds to MYD88 protein]
|
CTD |
PMID:25780291 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
| G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [cilostazol results in decreased susceptibility to TNF protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to NCF1 protein]]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to TNFRSF1A protein]]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of TNF mRNA; [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of TNF protein; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; zinc protoporphyrin inhibits the reaction [naringenin results in decreased activity of TNF protein]; zinc protoporphyrin inhibits the reaction [perflexane inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of TNF protein]]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF mRNA]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF protein] zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased localization of and results in increased activity of RELA protein]]; zinc protoporphyrin inhibits the reaction [manganese chloride promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]
|
CTD |
PMID:19608869 PMID:20052772 PMID:20131233 PMID:20360627 PMID:21660147 PMID:21925249 PMID:21963524 PMID:22709785 PMID:24095726 PMID:26747958 PMID:30261164 PMID:32621855 PMID:33049506 PMID:35691465 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tnfrsf1a
|
TNF receptor superfamily member 1A
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to TNFRSF1A protein]]]
|
CTD |
PMID:19608869 |
|
NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816
|
|
| G
|
Tnrc6a
|
trinucleotide repeat containing adaptor 6A
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of TNRC6A mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 1:186,992,457...187,146,764
Ensembl chr 1:186,992,504...187,146,756
|
|
| G
|
Tollip
|
toll interacting protein
|
decreases expression
|
EXP
|
zinc protoporphyrin results in decreased expression of TOLLIP protein
|
CTD |
PMID:25780291 |
|
NCBI chr 1:206,391,120...206,413,809
Ensembl chr 1:206,380,308...206,411,988
|
|
| G
|
Tp53
|
tumor protein p53
|
multiple interactions
|
ISO EXP
|
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [cobaltiprotoporphyrin results in increased expression of TP53 protein] zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of TP53 protein] zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]]
|
CTD |
PMID:18042465 PMID:20357190 PMID:22763982 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
| G
|
Traf6
|
TNF receptor associated factor 6
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [TRAF6 protein binds to MYD88 protein]
|
CTD |
PMID:25780291 |
|
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328
|
|
| G
|
Ubxn2a
|
UBX domain protein 2A
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of UBXN2A mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:33,603,804...33,645,958
Ensembl chr 6:33,603,804...33,632,202 Ensembl chr20:33,603,804...33,632,202
|
|
| G
|
Usp13
|
ubiquitin specific peptidase 13
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of USP13 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:117,502,811...117,617,049
Ensembl chr 2:117,505,122...117,630,161
|
|
| G
|
Usp34
|
ubiquitin specific peptidase 34
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of USP34 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr14:101,487,110...101,677,519
Ensembl chr14:101,487,153...101,678,632
|
|
| G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of VCAM1 mRNA]
|
CTD |
PMID:19608869 PMID:23892052 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
| G
|
Vdr
|
vitamin D receptor
|
affects abundance
|
ISO
|
VDR gene polymorphism affects the abundance of zinc protoporphyrin
|
CTD |
PMID:25963508 |
|
NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:130,866,745...130,916,757
|
|
| G
|
Vps33a
|
VPS33A core subunit of CORVET and HOPS complexes
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of VPS33A mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr12:38,685,484...38,710,668
Ensembl chr12:38,685,538...38,712,277
|
|
| G
|
Wsb2
|
WD repeat and SOCS box-containing 2
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of WSB2 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr12:44,878,483...44,899,474
Ensembl chr12:44,878,509...44,899,474
|
|
| G
|
Zfp36
|
zinc finger protein 36
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [Nicotine results in increased expression of ZFP36 mRNA]
|
CTD |
PMID:24095726 |
|
NCBI chr 1:92,796,628...92,799,108
Ensembl chr 1:92,796,628...92,799,108
|
|
| G
|
Zfp827
|
zinc finger protein 827
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ZNF827 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr19:45,624,849...45,791,739
Ensembl chr19:45,614,604...45,844,430
|
|
| G
|
Zfyve16
|
zinc finger FYVE-type containing 16
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of ZFYVE16 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:25,448,264...25,495,180
Ensembl chr 2:25,448,829...25,483,295
|
|